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Summary
HIV-1 resistance is one of the problems affecting success of antiretroviral therapy programmes 
worldwide. The extent of drug resistance differs in different parts of the globe, countries and 
regions  depending  on  several  factors  such  as  effectiveness  of  the  regimens,  ART  options 
available,  duration  of  the  ART  programmes,  degree  of  drug  adherence,  infrastructure  and 
logistics support, ART policies and funds to support the programmes.
In Tanzania, ART programmes started officially in the countries in 2004. With more than 1.4 
million  people  affected  in  the  country,  the  government  alone  cannot  support  its  ART 
programmes,  as a results  it  seeks cooperation from other stake holders such as international 
organizations and agencies and donor countries. With this initiative at least 235 000 (equivalent 
to 50% of 422, 000) of people in need of ART could get them by 2009. Many studies on efficacy 
of  ART  programmes,  specifically  on  drug  resistance,  have  been  conducted  in  developed 
countries but not in developing countries due to lack of resources.  So many tests  have been 
optimized for HIV-1 subtype B which is prevalent in the developed countries but not for non-
subtype B which is the main HIV-1 subtype in developing world. Some few studies have been 
conducted in Tanzania to evaluate the efficacy of the ART regimens and programmes. These 
studies  have  evaluated  either  the  virological  efficacy  and  genotypic  resistance  in  patients 
receiving ART (to evaluate development of acquired resistance) or genotypic resistance in drug 
naïve patients (to assess primary resistance). These few studies have been conducted in cities or 
urban areas with referral hospitals and have indeed shown some degree of resistance to ART and 
have provided some insights into degree of  resistance  in  Tanzania,  particularly in  the urban 
areas. Most studies have not reached in the rural areas to investigate the pattern of resistance in 
these parts of the country. 
x
Summary
This  study was conducted to  monitor  HIV-1 drug resistance in  Ifakara  HIV/AIDS cohort,  a 
cohort that was established in 2004 as one of the first sites chosen for ART rollout in Tanzania.  
This cohort is integrated in the Center for Decease and Control of Ifakara Referral  Hospital.  
Ifakara referral hospital serves a population of about 600 000 in Ifakara and Ulanga districts in 
Morogoro region, South East Tanzania, an area with about 30 000 people estimated to be living 
with HIV/AIDS. By October, 2011 the cumulative number of patients enrolled in this cohort was 
5748 and a total of 3940 had been started on ART. So the first question in this study was to set to 
answer as to what extent is there a problem of drug resistance in this cohort and if there is a trend 
over  time  to  this  resistance.  The  other  aim was  to  genotype  samples  from all  patients  with 
suspected clinical resistance. The third component of the study was other was to develop and 
validate a microarray tool for detection of resistance mutations to reverse transcriptase inhibitors 
which are the main drugs used as first line drugs in the Ifakara HIV-1 cohort. 
To answer the first question, 187 and 200 randomly collected samples in 2005-2007 and 2009 
respectively, from drug naïve HIV patients were processed in Ifakara, Tanzania, and CD4 assay 
was performed. The remaining aliquot were sent to Basel, Switzerland for viral load assay and 
molecular  genotyping  to  identify  resistance  mutations  known  to  affect  reverse  transcriptase 
inhibitors  and  protease  inhibitors  which  are  the  only  official  class  of  ART  drugs  used  in 
Tanzania and Ifakara cohort. The reverse transcriptase and protease genes of the viral DNA were 
sequenced and the sequences were submitted to Stanford University HIV drug resistance data 
base to get information on resistance and HIV subtypes. 
Major drug resistance mutations were detected in 8.4% and 3.3% of analyzed samples in RT 
gene in 2005-2007 and 2009 respectively.  The observed difference in resistance mutations in 
2005-7 and 2009 was not statistically significant. The subtypes identified in 2005-7 were A (28.0 
xi
Summary
%), C (37.3%), D (24.0%) and CRF01_AE (10.7%). The subtype % frequencies in 2009 were as 
follows: A (24.2), C (45), D (17.5), CRF01_AE (7.5), B (5) and F (0.8). The pattern of HIV-1 
subtypes observed in 2005-7 and 2009 were almost similar with the exception for the occurrence 
of five isolates of HIV-1 subtype B and one isolate of HIV-1 subtype F in 2009. This pattern was 
similar to the one observed in other earlier studies in Tanzania which identified HIV-1 subtypes 
C, A and D as main HIV-1 subtypes in Tanzania.  However,  as with the other studies, local  
subtype prevalence variation was also observed. 
A follow up sample was also taken from the first samples collected in 2005-7 (patients who had 
started ART for an average duration of 11 months), so as to assess the development of acquired 
resistance.  A total  of 16 samples could be successfully genotyped and major drug resistance 
mutation to reverse transcriptase inhibitors were detected in two patients (12.5%). In the last 
analysis from 17 suspected clinical resistance cases 6 patient samples (35.3%) were idenfied to 
harbour major resistance mutations to reverse transcriptase inhibitors. No major drug resistance 
mutations  to  protease  inhibitors  were  detected  in  all  the  samples  analyzed,  but  only  minor 
protease resistance mutations were observed. Resistance mutations were present in only one third 
of patients with suspected resistance,  suggesting other factors may have played a role in the 
observed lower ART response in these patients. In general the ART response was good in the 
cohort. However, the low level of drug resistance observed likely could affect the ART program 
in the area.
The microarray was developed and optimized using 4 HIV-1 cloned RT fragments from Swiss 
HIV cohort patients and 102 samples from Ifakara cohort HIV patients. Overall the microarray 
had a sensitivity of 92 percent. One main challenge was a high level of failure to produce signals 
which could be due to either primer mismatch leading to failure in primer extension reaction or 
xii
Summary
due to failure in the hybridization step. The disadvantages of this microarray are that it is only 
optimized for Ifakara HIV sequences and it can only test the selected mutations on the array and 
may not therefore be used as a diagnostic tool. The advantage of this microarray over direct 
sequencing is that it is relatively cheap and it takes less time to get results. In order to make this 
microarray suitable for population studies, further optimization is required.
xiii
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1.1 HIV/AIDS 
Acquired Immunodeficiency Syndrome (AIDS) was first reported in 1981. In 1983 its causative 
agent was discovered and was named Human Immunodeficiency Virus (HIV) [1]. Since then the 
disease has spread across the globe and has caused tremendous public  health problems. The 
UNAIDS 2010  –  Joint  United  Nations  Programme  on  HIV/AIDS reported  in  2010  that  an 
estimated 0.5% of the world’s population (about 34 million people) were living with HIV/AIDS 
(PLAIDS), 68% of whom were living in Sub-Saharan Africa [2].
1.2 HIV-1 structure and its genome organization
1.2.1 The HIV viral envelope
HIV-1 virus is spherical in shape and has a diameter of 1/10,000 of a millimeter. The virus is 
made up of an outer coat envelope composed of a lipid bilayer membrane that is derived from a 
host cell when a new virion buds from the cell. The HIV Env protein is found throughout the 
viral envelope and consists of a cap made of glycoprotein 120 (gp120), and transmembrane (TM) 
gyclycoprotein 41 (gp41) molecules [3]. 
1.2.2 The viral core
Inside the viral envelope is a capsid core made up of several copies (about 2000) of the viral 
protein, p24. The capsid surrounds two copies of genomic HIV RNAs. The HIV core contains a 
nucleocapsid protein (p7), the enzymes reverse transcriptase (RT), protease (PR) and integrase 
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(IN), and the HIV matrix protein (p17) [3]. The structure of Mature HIV particle is as shown in 
Figure 1-1. 
Figure  1-1.  A mature  HIV-1 particle.  The  positions  of  the  major  viral  proteins,  the  viral 
envelope, and genomic RNA are shown. Taken from Freed, 2001(Somatic Cell and Molecular 
Genetics, Vol. 26, Nos. 1/6, November 2001).
1.2.3 HIV-1 genome organization
The HIV genome has 3 major genes that encode structural and non-structural proteins namely 
gag (group-specific antigen), pol (polymerase), and env (envelope glycoprotein). In addition, the 
HIV has six regulatory genes (tat, rev, nef, vif, vpr, and vpu) that contain information needed to 
produce proteins that control the ability of HIV to infect a cell, produce new copies of virus, or 
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responsible  for  pathogenicity  of  the  virus  [3].  The  functions  of  these  genes  are  highlighted 
below.
The Major genes:
Gag gene-encode Pr55Gag polyprotein. This polyprotein is cleaved by the viral PR enzyme 
into four mature proteins:
1. Matrix (MA) or p17
2. Capsid (CA) or p24
3. Nucleocapsid (NC) or p7
4. p6
Pol gene-encodes Pr160GagPol polyprotein. This polyprotein is subsequently cleaved by 
viral protease into PR, RT, and IN enzymes.
Env: The env gylcoproteins are synthesized as a polyprotein precursor and are cleaved by a 
cellular protease into the surface protein gp120 (interacts with the receptor and co-
receptors on the host cell during viral entry process) and a transmembrane (TM) 
glycoprotein, gp41 (anchors the gp120/gp41 complex in the viral membrane).
The regulatory/accessory genes:
Transcriptional activator (Tat): this is a protein that is involved in regulation of HIV 
transcription by increasing the efficiency of transcriptional elongation through its 
interaction with RNA polymerase II and Tat-associated kinase (TAK) complex (cyclin-
dependent kinase (cdk9) and cyclin T (cycT)) [4].
Rev: this protein binds to a Rev response element (RRE) present in all unspliced viral 
mRNAs, and is involved in nuclear export of these mRNAs[4] .
The Viral protein U (Vpu): this gene encodes a viral protein that binds CD4 in the 
endoplasmic reticulum (ER) and targets it for proteolysis by recruitment into the 
cytosolic ubiquitin-proteasome pathway [5].
4
Introduction
 Nef: this protein is involved in removal of CD4 on the cell surface by accelerating 
endocytosis and is also associated with downregulation of expression of major 
histocompatiblity complex (MHC-I) molecules on the surface of infected host cell [5] 
[6]. 
The Viral infectivity factor (VIF) promotes infectivity of viral particles by preventing 
APOBEC3G from being incorporated into HIV-1 particles and thereby preventing 
premature termination of the viral replication. APOBEC3G is responsible for dC to dU 
mutations in the viral minus strand DNA during reverse transcription, resulting in G to 
A substitutions in the viral plus (genomic) strand [7].
 Viral protein R (VPR), has been proposed to have functions of long terminal repeat 
transactivation, nuclear import of the preintegration complex (PIC), induction of cell 
cycle arrest, and apoptosis [8].
The positions of the HIV-1 major genes and genes of regulatory and accessory proteins are as 
shown in Figure 1-2.
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Figure  1-2.  Organization of  the HIV-1 genome.  The positions of the HIV-1 open reading 
frames gag, pol, env, vif, vpr, vpu, nef, tat, and rev are indicated. The ψ indicates the position of 
the RNA packaging signal. The Gag spacer peptides (p2 and p1) positions are indicated. The 
“myr” is a site of Gag N-terminal myristylation.  Taken from Freed, 2001 (Somatic  Cell  and 
Molecular Genetics, Vol. 26, Nos. 1/6, November 2001).
1.3 HIV-1 replication cycle
HIV  replication  cycle  has  several  steps  involving  virus  binding  to  host  cell  membrane, 
membrane fusion, uncoating, reverse transcription, nuclear import and integration, transcription 
of viral genome and synthesis of viral enzymes and structural proteins, assembly, budding and 
maturation.  Only some steps of the replication cycle  are of particular relevance for this PhD 
project and are therefore presented in greater detail below. 
1.3.1 Reverse transcription
HIV-1 reverse transcribes each of its two RNA genome into double-stranded DNA just after 
entry into the host cell. The reverse transcription process involves several steps [15]. These steps 
have been described by Freed (2001) [3] as shown briefly below:
A primer tRNA binds the primer binding site (pbs). DNA synthesis proceeds to the 5' end of 
the RNA strand to generate a DNA/RNA hybrid.
The RNaseH activity of the RT enzyme degrades the RNA portion of the DNA/RNA hybrid 
to generate a minus-strand strong stop DNA.
The minus-strand strong stop DNA makes the first strand transfer from the 5' to the 3' end of 
the genome by using short regions of homology called “R” regions. 
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 Minus-strand synthesis occurs by using the 3' end of the minus-strand strong stop DNA as a 
primer.
Plus-strand synthesis occur using fragments of RNA remaining from minus-strand synthesis 
as primers. The primary site of priming takes place at a purine-rich sequence, polypurine 
tract (PPT) and the central PPT.  
RNaseH then removes the tRNA from the pbs to allow second-strand transfer to take place.
Plus-strand synthesis proceeds to the end of the minus strand. 
The HIV-1 RT enzyme is prone to make errors while copying its genome, due to lacky of proof 
reading activity, as a result some mutations may develop which may either be harfmful to the 
virus  (replication  is  hindered)  or  beneficial  (virus  becomes  more  fit,  and  replicates  more 
efficiently). Some of these mutations may be selected under drug pressure (acquired resistance) 
and makes antiretroviral drugs less effective [3]. 
1.4 The HIV-1 molecular epidemiology
1.4.1 HIV-1 subtypes and their distribution
HIV infection  is  characterised  by high  levels  of  virus  production  and turnover.  The reverse 
transcription  of  viral  RNA into  DNA is  highly  prone  to  errors  introducing  on  average  one 
mutation for each viral genome transcribed [24] [25]. The high rate of HIV replication, combined 
with the high mutation rate that occur during the viral replication cycle ensures that patients 
harbour a complex and diverse mixture of viral genotypes (quasispecies), each differing by one 
or more mutations. Some of these mutations confer a selective advantage to the virus such as 
decreased  susceptibility  to  antiretroviral  drugs  [26].  Globally,  the  HIV  prevalence  and 
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epidemiological pattern is unevenly distributed [27]. The two groups of HIV-2, A and B, are 
restricted  in  West  Africa  [28].  HIV-1  group  M  viruses  are  more  pathogenic  and 
epidemiologically diverse and account for almost the entire global epidemic. HIV-1 group M is 
further divided into nine genetically distinct subtypes A, B, C, D, F, G, H, J, and K [15]. In 
addition, more than 40 circulating recombinant forms (CRFs) have been recognized so far [30]. 
The most important strains that cause the global epidemic are subtypes A, B, C, D, CRF01_AE 
and CRF02_AG [29] [27] [31].  The regional  and global  distribution of HIV-1 subtypes  and 
global prevalence of HIV-1 in 2004-2007 is as shown in Figure 1-3 and Figure 1-4.
Figure 1-3. The global distribution of HIV-1 subtypes in 2004/7 and HIV-1 prevalence in 
2004-2007. Taken from Skar et al, 2011 (Annals of New York Academy of Science. 1230 (2011) 
108–118). 
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Figure 1-4. Global distribution of HIV-1 subtypes in 2007. Taken from Hemelaar et al., 2011 
(AIDS, Volume 25(5), 13 March 2011, p 679–689).
1.4.2 The epidemiological, clinical and diagnostic impact of HIV-1 diversity
The  genetic  variation  of  HIV-1  differs  between  and  within  subtypes.  The  within-subtype 
variation may be as high as 8 to 17%, and the variation between subtypes can be as high as 17 to  
35%, depending on the subtypes and genome regions examined [18]. It has been shown that this 
HIV-1 diversity impacts diagnosis and viral  load measurements  [33].  Other researchers have 
observed  that  the  HIV diversity  may  affect  the  response  to  antiretroviral  treatment  and  the 
emergence of drug resistance [29] [34] [35]. Subtypes may be transmitted at different rates and 
may exhibit differences in the rate of disease progression [36] [37]. The high diversity of HIV 
has also been shown to limit the intra- and inter- subtype cross-reactivity of immune responses 
[38]. Due to a rapid selection of immune escape viral mutants following infection, the viruses 
cannot be eliminated by the host’s immune response [39]. This has hampered efforts towards 
development of effective vaccines [39]. 
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1.5 HIV-1 antiretroviral therapy
1.5.1 Principles and targets for HIV chemotherapy
HIV drugs interrupt the replication circle of the virus during attachment and fusion to the host 
cell  surface,  reverse  transcription,  integration  into  host  genome  and maturation  of  the  virus 
particles  [40].  There  are  four  classes  of  drugs  currently  used  to  treat  HIV type  1  (HIV-1) 
infection.  These  are:  Nucleoside  Reverse  Transcription  Inhibitors  (NRTIs),  Non-Nucleoside 
Reverse Transcription Inhibitors (NNRTIs), Protease inhibitors (PIs) and Fusion Inhibitors (FIs). 
Recently a new drug, Raltegravir, which is an integrase inhibitor, has been approved by Food 
and Drug Association (FDA) of the United States of America [41]. A summary of important HIV 
drugs and their targets is shown in  Table 1-1. According to current treatment standards, HIV 
antiretrovirals are combined for triple combination therapy termed highly active antiretroviral 
therapy (HAART), in order to effectively suppress the viral replication by targeting more than 
one drug target. Generally drugs are combined as follows:
2 NRTI + 1 NNRTI
2 NRTI + 1 PI
3 NRTI
The World Health Organization (WHO) provides recommendation on first and second line drugs 
[2]. The WHO recommended that abacavir (ABC) and didanosine (ddI) be considered as backup 
options whenever there is azidovudine (AZT) or tenofovir (TDF) toxicity or contraindication.
Table 1-1. Important HIV-1 Drugs and their Targets
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Drug Group Target
*Zidovudine NRTIs RT enzyme
*Didanosine
Zalcitabine 
*Stavudine
*Lamivudine
*Abacavir
Emtricitabine
Tenofovir 
disoproxil
Saquinavir PIs PR Enzyme
*Ritonavir
Indinavir
Amprenavir
Nelfinavir
*Lopinavir
Atazanavir
*Nevirapine NNRTIs RT Enzyme
Delavirdine
*Efavirenz
Raltegravir IN inhibitors IN enzyme
Enfuvirtide Fusion Inhibitor Viral gp41
Maraviroc Chemokine Antagonists Chemokine Receptor 5 
(CCR5)
* Drugs that are used in Tanzania and in Ifakara Cohort  
1.5.2 Nucleoside Reverse Transcription Inhibitors
The NRTIs blocks the action of HIV  RT enzyme [42]. Chemically modified nucleosides and 
nucleotides (analogs) are incorporated in place of natural nucleotide into the viral DNA during 
reverse transcription of viral RNA into cDNA. These modified nucleotides lack an OH group at 
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the 3` position of the ribose. Their incorporation terminates the replication of HIV DNA, thus 
inhibiting the multiplication of the virus [26] [43].
1.5.3 Non-Nucleoside Reverse Transcription Inhibitors
NNRTIs target RT, but in a different way than NRTIs do. The NNRTIs help stop HIV replication 
by attaching to the hydrophobic pocket located close to the catalytic site of the RT, preventing it 
from transcribing viral RNA into DNA [44] [45].
1.5.4 Protease inhibitors
PIs target the HIV PR enzyme which cleaves the gag-pol polyprotein of the virus into essential  
functional proteins during the maturation process of the virion. If the polyprotein is not cleaved, 
the virus fails to mature and is incapable of infecting a new cell. PIs bind to the active site in the 
protease enzyme where protein cleaving occurs, and so prevent the release of individual mature 
particles [46]. 
1.5.5 Fusion Inhibitors
Viral entry is a complex process that involves binding of viral envelope protein, gp120 to CD4 
receptors  on  the  target  cell  followed  by binding to  a  co-receptor,  CCR5 or  CXCR4.  These 
interactions  induce  a  conformational  change  on  gp  120  which  exposes  the  transmembrane 
protein gp41. Gp41 has an N- terminal domain, two heptad repeats, HR1 and HR2, and a C-
terminal domain. After exposure of gp41, the HR2 domain zips around HRI and together they 
form a  six-helix  bundle.  This  conformation  change  in  gp41  brings  the  viral  and  target  cell 
membranes together and allows fusion to proceed. Inhibitors such as Enfuvirtide or T-1249 are 
peptides that mimic HR2 and bind to HR1. This inhibits the HR2 zipping process and prevents 
fusion [47] [48] [49].     
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1.5.6 Integrase Inhibitors
Integration of HIV-1 proviral DNA into the host cell genome occurs in three steps that involve 
incision of proviral and host DNA and ligation by the integrase enzyme [50]. The first step is the 
processing of the 3′ ends of proviral DNA in which the enzyme removes two nucleotides from 
each end leaving the dinucleotide ``CA`` at the 3′ ends. Moreover, integrase cleaves the human 
DNA at  the  site  of  integration  5  bases  apart.  In  a  second  step,  termed  strand  transfer,  the 
integrase enzyme joins the previously processed 3′ ends to the 5′ ends of target DNA at the site 
of integration. The third step is an enzymatic removal of two unpaired nucleotides at the 5`-ends 
of  the  viral  DNA by cellular  enzymes  [41].  Integrase  inhibitors  bind  to  the  strand  transfer 
complex of integrase blocking the insertion of the processed HIV-1 DNA strand into the host 
DNA [51] [52]. 
1.6 The Reverse Transcriptase Enzyme
HIV-1 RT is a heterodimer of a 66-kDa molecular mass subunit (p66) and a 51-kDa molecular 
mass subunit (p51). DNA polymerase and RNase H catalytic activities are both conferred by the 
larger p66 subunit [53].  Figure 1-5 depicts the interaction of HIV-1 RT with dNTPs, NNRTI. 
This image also shows the primer- template RNA interaction discussed above in section 1.3.1
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Figure  1-5. HIV-1 RT enzyme with substrates.  dNTP (green),  NNRTI (yellow),  the DNA 
primer  (light  gray),   template  (dark  gray),  fingers  (blue),  palm  (purple),  thumb  (green), 
connection (yellow), and RNaseH (red) the p66 subunit,  and p51 subunit (white). The region 
circled is the polymerase active site and NNRTI-binding pocket. Taken from Pata et al., 2004 
(PNAS, July 20, 2004, Vol. 101, No. 29, p 10548–10553)
1.7 The Protease Enzyme
The HIV PR is a C2-symmetric homodimeric enzyme consisting of two monomers of 99 amino 
acid each [54]. The HIV PR has an extended beta-sheet known as the flap, which constitutes in 
part  the  substrate  binding  site.  Each  flexible  flap  contains  side  chains  that  extend  outward 
(Met46, Phe53), hydrophobic chains extending inward (Ile47, Ile54), and a glycine rich region 
(Gly48, 49, 51, 52). The dimeric active site triad `AspThrGly' is in amino acid positions 25 to 27 
and 25´ to 27´, respectively. Each monomer contains an aspartic acid residue (Asp-25 and Asp-
25´) that is essential for catalysis. The two residues of Asp25 and Asp25´ do interact directly 
with the substrate or the inhibitor. 
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1.8 The HIV-1 Intergrase
The HIV-1 integrase enzyme is comprised of three domains; catalytic core domain, N-terminal 
domain  and  C-terminal  domain.  The  catalytic  core  domain  contains  a  D,D-35-E  motif, 
comprising  residues  Asp64,  Asp116,  and Glu152.  It  has  been proposed that  coordination  of 
divalent metal ion to these residues plays a key role in catalysis [41] [56]. It is also thought that 
the C-terminal domain binds DNA nonspecifically [58] or interacts with a subterminal region 
just inside the very ends of the viral DNA end [59]. 
1.9 HIV-1 drug resistance 
1.9.1 Primary and acquired drug resistance
HIV resistance to antiretroviral therapy can be divided into two categories, namely primary and 
secondary resistance. Primary resistance reflects acquisition of a drug-resistant strain of HIV by 
a newly infected person, while secondary or acquired resistance develops after a period of HIV 
treatment [60].
1.9.2 Mechanism of resistance to NRTIs
There are two mechanisms that have been observed to be responsible for development of HIV-1 
drug resistance. For nucleoside and nucleotide analogues resistance is brought about by either 
impairment of the incorporation of these molecules into the synthesised DNA strand (Figure 1-1) 
or their removal from the terminated DNA strand (Figure 1-7) [42] [61] [62]. The impairment of 
drug incorporation is due to mutations in the catalytic site of the RT enzyme which compromise 
attachment of the base analogues at the active site of the enzyme [40]. They include M184V 
mutation (main mutation that confers resistance to lamivudine), Q151M complex of mutations 
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(confer resistance to most NRTIs such as stravudine and didanosine but not lamivudine and 
tenofovir),  and the K65R mutation (confers resistance to most  NRTIs such as tenofovir  and 
abacavir but not zidovudine). The mutations at codons 41, 67, 70, 210, 215, and 219 of reverse 
transcriptase  enzyme  are  collectively  referred  to  as  thymidine  analog  mutations  (TAMs),  or 
nucleotide  excision mutations.  The TAMs are removed from the terminated  DNA strand by 
pyrophosphorolysis.  The  removal  of  the  analogue  from the  terminated  DNA chain  involves 
pyrophosphate or adenosine 5´-triphosphate acting as an acceptor molecule for the removal of 
the drug [62] [63]. In addition, a six base pair insertion at position 69 (T69S) of the reverse 
transcriptase enzyme contributes to class-wide resistance [64]. 
Figure  1-6.  Resistance to NRTIs by interference with the incorporation of  a nucleoside 
analogue.  Taken  from Clavel  and  Hance,  2004  (New  England  Journal  of  Medicine,  2004; 
350:1023-1035).
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Figure  1-7.  Resistance to NRTIs by ATP-mediated excision of  the nucleoside  analogue. 
Taken from Clavel and Hance, 2004 (New England Journal of Medicine, 2004; 350:1023-1035).
1.9.3 Mechanism of resistance to NNRTIs
Development of resistance to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) occurs 
as a result  of mutations in a hydrophobic pocket located adjacent to the catalytic  site of the 
reverse transcriptase enzyme which affect the binding of these agents to the enzyme [65]. The 
binding of the inhibitor to the hydrophobic pocket of reverse transcriptase interferes with  its 
ability to synthesise DNA [66]. Resistance to nevirapine, for example, is mainly due to Y181C 
mutation, but other mutations, such as Y188C, K103N, G190A, and V106A, do also take part. 
Efavirenz resistance is mainly due the K103N mutation, and to a small extent Y188L mutation 
[67] [68] [69]. 
1.9.4 Mechanism of resistance to PIs
Resistance to PIs is due to amino acid substitutions inside or adjacent to the substrate-binding 
domain of the protease enzyme which reduces the affinity of the inhibitors to the enzyme [70]. 
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These amino acid changes modify the number and the nature of the points of contact between the 
inhibitors and the protease, resulting into overall reduction in their affinity for the enzyme. The 
V82A mutation, for example, reduces the size of an amino acid residue in the protease that is  
more important for binding most inhibitors than for binding the natural viral substrate. Protease 
inhibitors have been designed to bind the protease with maximal affinity and tend to occupy 
more space inside the active site cavity than do natural  substrates.  Unlike the inhibitors,  the 
natural substrates of the protease have a less tight interaction with the catalytic site. Resistance 
mutations in the protease result in an overall enlargement of the catalytic  site of the enzyme 
affecting the binding of inhibitors than the natural templates [71].
1.9.5 Mechanism of resistance to INIs
Resistance  to  raltegravir  is  caused  by  mutations  involving  amino  acid  residues  148 
(Q148H/K/R),  155 (N155H) and to a lesser extent  143 (Y143C/H/R) of integrase  [72] [73]. 
Q148 is located on the active site flexible loop that consist of residues 140 to 148, involved in 
catalytic core domain–DNA contacts [74] [75]. The N155H and Y143R/C mutations have been 
shown to reduce the replication capacity of the virus by impairing strand transfer activity and to 
some extent 3′ processing activity [76]. 
1.9.6 Resistance to Fusion Inhibitors
Resistance to fusion inhibitors occurs as a result of mutations at positions 36-45 in the HR1 
domain, particularly in the 3 conserved  amino acid positions 36, 37 and 38 of gp41 [79]. As a 
result, fusion inhibitors are unable to bind to gp 41 due to conformational changes in gp41 [80]. 
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1.10 Monitoring of HIV-1 drug resistance
1.10.1 Reasons for HIV-1 Drug resistance monitoring
In resource-limited settings where antiretroviral treatment (ART) is being scaled-up, the World 
Health Organization (WHO) recommends the surveillance of transmitted HIV drug resistance 
[81]. The purpose of monitoring HIV Drug Resistance (HIVDR) emerging in populations is to 
assess the effectiveness of ART programmes and minimising the spread of HIVDR following the 
use of antiretroviral treatment. Where drug resistance emerges, the data collected will inform the 
guidelines on appropriate population-based first- and second-line regimens, indications for time-
of-regimen switch  on a  population  basis,  and specific  actions  to  improve outcomes of  ART 
programmes. Phenotypic and genotypic assay are two types of assays available to measure ARV 
drug resistance. A third, assay is a virtual Phenotype, in which genotyping data from the patient’s 
virus are used to interrogate a large database of previously determined and paired HIV genotypes 
and phenotypes. 
1.10.2 Phenotypic drug resistance testing
The  phenotypic  assays  are  based  on  generation  of  a  recombinant  HIV-1.  To  generate  a 
recombinant HIV-1 for assaying PRIs and RTIs resistance, the PR and RT genes of HIV-1 are 
amplified  from  a  patient’s  sample  and  the  amplified  products  are  inserted  into  a  plasmid 
containing a HIV backbone where the PR and RT genes had been deleted [82]. The fold change 
in drug concentration required to inhibit the recombinant HIV-1 is compared to that required for 
a  wild  type  reference  strain.  The  result  is  then  expressed  as  IC50,  which  is  defined  as  the 
concentration of the drug required to inhibit the virus replication by 50% [83].  
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1.10.3 Genotypic Drug Resistance Testing
The HIV-1 genotypic tests assess known mutations associated with drug resistance in the HIV-1 
drug targets such as PR and RT [84]. The RNA extracted from replicating HIV-1, is amplified by 
PCR  and  the  PCR  products  are  then  analyed  after  performing  a  sequencing  reaction  or 
hybridisation-based method. The advantage of sequencing is that it determines the entire set of 
mutations when present in the gene which is analyzed while hybridization examines only the 
specific mutations of interest in that gene [84].
1.10.4 Dideoxynucleotide sequencing
This  is  the  standard  methodology  utilized  for  testing  ARV drug  resistance  worldwide.  The 
deoxynucleotide  triphosphates  (dNTPs)  and  dideoxynucleotide  triphosphates  (ddNTPs)  are 
added per each sequencing reaction in the presence of specific primers [85]. The incorporation of 
ddNTPs during DNA synthesis leads to chain termination, finally generating numerous single 
stranded DNA of varying lengths, differing from each other by one nucleotide length. The DNA 
strands containing labelled primers  or ddNTPs are separated by capillary electrophoresis  and 
detected by fluorometric methods in an automated sequencer. This direct sequencing of the PCR 
amplified RT gene is known as viral population-based sequencing. The sequences generated are 
edited with sequencing analysis software and submitted online to the HIV-1 drug resistance data 
bases such as Stanford University HIV drug resistance database for prediction of drug resistance 
[85]. 
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1.10.5 Hybridization based methods
The specific drug-resistance mutations from amplified RNA can be analyzed in a microarray. 
The process involves several steps: amplification of target viral RNA by RT-PCR, PCR, in vitro 
transcription using labelled ddNTPs, hybridization of the labelled amplicons with DNA probes 
on the microarray and the scanning of the probe arrays with a microarray scanner. The data from 
the scanned array are then analysed by using a special microarray software [86].
1.10.6 SNPs Genotyping   
Single nucleotide polymorphisms (SNPs) are the most common type of genetic variations which 
involve a single base pair mutation in a DNA, [87]. There are number of methods that can be 
used for SNP genotyping and each of these technologies has its advantages and disadvantages 
when  weighed  in  terms  of  robustness,  cost,  high-throughput,  simplicity,  specificity  and 
sensitivity [88].
1.11 DNA microarray technology
1.11.1 Basic concept of DNA microarray
A DNA microarray consists of a solid support, usually glass, with unique nucleic acid sequences 
(probes)  bound  at  discrete  positions  on  the  solid  support.  Microarray  technology  uses  the 
principles of DNA hybridization. Sequences from a labelled target are recognised by the specific 
and  complementary  oligonucleotide  probes  on  the  microarray  [89].  The  probes  are  DNA 
sequence bound to the solid-surface support in the microarray, while the target is the unknown 
sequence of interest to be analyzed. In general terms, probes are synthesized and immobilized as 
discrete features, or spots. Each feature contains millions of copies of identical probes. The target 
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is fluorescently labeled and then hybridized to the probe microarray. A successful hybridization 
reaction  between the  labeled  target  and the  immobilized  probe  will  result  in  an  increase  of 
fluorescence  intensity  over  a  background  level,  which  can  be  measured  using  a  fluorescent 
scanner  [90].  Microarrays  fall  into  five  categories;  printed  microarrays,  in-situ  synthesized 
oligonucleotide  microarrays,  high-density  bead arrays,  electronic  microarrays  and suspension 
bead arrays [90].  
1.11.2 Application of microarrays in research and diagnostics
Microarrays  are  potential  molecular  tools  for  research,  drug discovery  and diagnostics  [95]. 
Microarray  technology  has  been  used  to  investigate  the  differential  gene  expression  of 
pathogens,  to  the  detection  and  identification  of  various  pathogens,  pathogen  discovery, 
antimicrobial resistance monitoring, and strain typing [90]. 
1.12 The Global statistics of HIV and AIDS
The UNAIDS 2010 – Joint United Nations Programme on HIV/AIDS reported in 2010 that about 
34 million people were living with HIV/AIDS globally, and Sub-Saharan Africa alone accounted 
for 68% of this global burden. In this report, Tanzania was among the top five countries with the 
highest number of PLAIDS that accounted 1.4 million people. The disease is estimated to cause 
1.8 million deaths per year globally and a global GDP loss of USD 52.3 billion [1]. The 
HIV/AIDS statistics in 2009 is summarized in  and Figure 1-8. 
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Table 1-2. Regional HIV/AIDS statistics in 2009. Source: Global report, WHO/UNAIDS 
(2010).
Region
Adult and 
children 
living with 
HIV
Adult % 
prevalence
(15-49)
Adult and child 
deaths due to 
AIDS
Sub-Saharan Africa 22.5 million 5.0 1.3 million
Middle East,  North Africa 460 000 0.2 24 000
South and South-East Asia 4.1 million 0.3 260 000
East Asia 770 000 0.1 36 000
Central and South America 1.4 million 0.5 58 000
Caribbean 240 000 1.0 12 000
Eastern Europe, Central Asia 1.4 million 0.8 76 000
Western and Central Europe 820 000 0.2 8500
North America 1.5 million 0.5 26 000
Oceania 57 000 0.3 1400
Total 33.3 million 0.8 1.8 million
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Figure  1-8.  Adults and children estimated to be living with HIV/AIDS in 2009.  Source: 
Global Report, WHO/UNAIDS (2010).
1.13 Statistics of HIV/AIDS in Africa
The North Africa region is  least  affected  with HIV/AIDS area in  Africa,  and there are  few 
statistics for prevalence of HIV/AIDS in this region. However, it was estimated in 2009 that the 
number of people living with HIV/AIDS in North Africa and Middle East was 400 000 - 530 
000. The prevalence of HIV/AIDS in West and Central Africa in adults in 2009 was estimated at  
around 2% in Benin, Burkina Faso, Democratic Republic of the Congo, Gambia, Ghana, Guinea, 
Liberia, Mali, Mauritania, Niger, Senegal, and Sierra Leone, while in Cameroon Gabon, Central 
African  Republic,  Nigeria  and  Côte  d’Ivoire  was  5.3%,  5.2%,  4.7%,  3.6%  and  3.4%, 
respectively.  East  and Southern  Africa  region is  the most  heavily affected  area  by the HIV 
epidemic accounting for almost 34% of people living with HIV/AIDS globally in 2009 [2].
1.14 HIV/AIDS in Tanzania
The first HIV case in Tanzania was reported in Kagera region in 1983 [92]. The disease has 
spread in all regions of Tanzania and by 2008 already 1.4 million people were infected by this 
virus. HIV/AIDS in Tanzania is caused by HIV-1 and the main subtypes involved are C, A, D 
and CRFs [92]. The prevalence of disease in Tanzania was estimated at 5.8% in 2008 but the 
prevalence  is  not  uniform across  the  regions  and age  groups,  being  higher  in  the  mainland 
regions than in the coastal areas and Zanzibar [93]. The most affected age group is between 15-
49  years  of  age  (35-39 years),  and  women  are  more  affected  than  men  [92].  The  regional 
distribution of HIV-1 in Tanzania in 2003-4 and 2007 is as shown in Figure 1-9.
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Figure 1-9. Trends by Region in HIV Prevalence in Tanzania between 2003-4 and 2007. 
Source:  Tanzania  HIV/AIDS  and  Malaria  Indicator  Survey  (THIMS)  2007-08 
(http://www.tacaids.go.tz/dmdocuments/THMIS%202007-08.pdf).
1.14.1 HIV-1 Transmission in Tanzania
In  Tanzania,  as  in  many  other  countries  of  Sub-Saharan  Africa,  the  main  routes  of  HIV-1 
transmission are:
sexual intercourse with infected partner
exposure to infected blood and blood products
mother to child transmission during pregnancy, delivery or breast feeding
to a lesser extent,  transmission from body fluids other than blood such as genital  secretions, 
cerebral-spinal fluid (CSF), pleural fluid and amniotic fluid [92]. 
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1.14.2 Risk factors for HIV-1 transmission in Tanzania
According to the UNGASS 2010 report [93], the main risk factors driving HIV-1 transmission in 
Tanzania are:
Age group: 35-39 years adults more affected than other age groups
Risky sexual acts: unprotected sex, commercial sex
Poverty/wealth: prevalence higher among richest and lower in poorest individuals
Socio-cultural  norms  and practices:  gender  inequality,  early  marriages,  female  circumcision, 
sharing injection needles among infected drugs users and other infected individuals
Promiscuity: prevalence higher in individuals with multiple sexual partners
sex: females more affected than males
marital status: prevalence higher in widowed women, divorced and separated women and lower 
in those who have never married
Location:  individuals in urban areas more affected than those in rural  areas, prevalence also 
higher in areas of high mobility like roadsides, prevalence higher in mainland Tanzania than in 
Zanzibar.
1.14.3 HIV-1 Treatment in Tanzania
Tanzania has a national guideline for management of HIV/AIDS through NACP. The NACP 
treatment guidelines are adopted from WHO guidelines. The care and treatment programme was 
initiated country-wide in 2004 and so far about 600 000 individuals require ART and have been 
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enrolled  in  care  and treatment  clinic  (CTC) centres.  Only  235 092 (55.6%) out  of  422 632 
eligible  ART patients  were on ART in 2009 at  563 CTCs throughout the country [92].  The 
NACP-recommended ART regimens for 2009 are summarized in Table 1-3.
Table 1-3. Recommended first and second line ART regimens in adults and children in Tanzania. 
Source: NACP, 2009 (National Guidelines for the management of HIV and AIDS, 2009).
Group First line regimen Second line regimen
Adults AZT + 3TC + NVP / EFV
d4T + 3TC + NVP / EFV 
TDF + FTC + EFV / NVP 
TDF + 3TC + EFV / NVP
ABC + ddI+ LPV/r or ATV/r
TDF + 3TC / FTC + LPV/r or ATV/r 
Children AZT + 3TC + NVP / EFV 
d4T + 3TC + NVP / EFV
 ABC + 3TC + EFV / NVP
ABC + ddI + LPV/r
1.14.4 HIV-1 Drug Resistance in Tanzania
Only few studies have been conducted in some regions of Tanzania to establish prevalence of 
resistance mutation either in drug naïve or in individuals on ART. These studies have been based 
either in the urban areas and referral hospitals like Dar es Salaam, Kilimanjaro and Kagera [94] 
[95] [96].
The  results  from  these  studies  have  indicated  slight  differences  in  the  prevalence  of  drug 
resistance mutations in drug naïve (primary or transmitted mutations) patients. In Dar es Salaam 
for example, Mosha and coworkers (2011) found a prevalence of 7% resistance to NRTIs and 
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9% resistance to NNRTIs in a study involving 13-25 year old youths attending the Infectious 
Disease Centre’s voluntary counselling clinic in Dar es Salaam from July 2004 to June 2005 
[94]. Nyombi and coworkers (2008) found a prevalence of 3% mutations for NRTIs and 4% to 
NNRTIs in infected pregnant women from  Kagera and Kilimanjaro in 2005 [95]. In each of 
these two studies NNRTI resistance seemed to be slightly higher than that of NRTI resistance. In 
the same study, a prevalence of 1.6 % for NRTI and 11.5% for NNRTI resistance was observed 
in women who had received single dose NVP (sdNVP). In another study conducted at Haydom 
Lutheran hospital in North East Tanzania  between November 2007 and June 2008, resistance 
mutations were detected at a prevalence of 3.9% in patients who had received ART for one year 
and 8.4% in patients that were on ART for two years [96]. These data suggest that the rate of 
resistance development is not uniform in different parts of Tanzania.
1.14.5 HIV-1 subtypes in Tanzania
Previous studies in Tanzania on HIV-1 sub-types are also limited and have been restricted to 
cities and towns with referral hospitals. In these studies the dominant subtypes observed were C, 
A,  D and CRFs  [97]  [98].  Table  1-4 summarizes  the  previous  data  on  HIV-1 sub-types  in 
Tanzania. The data shows that the distribution of subtype varies within Tanzania. For example, 
in Mbeya sub-type C is dominant followed by recombinant forms of sub-types C and A, subtype 
A prevails in Dar es Salaam, Kilimanjaro and Kagera. Subtype C is found at high prevalence in 
all the studied regions.
Table 1-4. Reported HIV-1 Subtype distribution in Tanzania
Dar es Salaam Kagera Kilimanjaro Mbeya
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Year July 2004 to 
January 2005
September 
to 
December 
2005
September to 
December 2005
September 
2002 to April 
2003
Sub-type percent 
Prevalence
A 36 31.8 36.0 18
C 36 27.3 25.0 43
D 14 19.7 20.0 3
CRFs 14 21.2 19.0 36
Gene analysed Pol Pol Pol Pol/Env 
Sample size 44 66 100 487
Reference cited [94] [98] [98] [99]
1.15 STUDY RATIONALE
Although it is universally recognised that combined ART has dramatically reduced HIV-related 
mortality [100], one major concern is the emergence and transmission of HIV drug resistant 
strains  at  the  population  level  as  a  consequence  of  uncontrolled  ART  usage  and  genetic 
mutations in the drug targeted genes [101] [102]. This could lead to the failure of basic ART 
programmes as well as strategies to prevent HIV morbidity and mortality [103]. Monitoring of 
HIV-1 drug resistance is recommended in patients initiating drugs or failing their first regimen in 
many countries  in  the developed world [87].  In  developing countries  like  Tanzania,  lack  of 
resources limit the use of drug resistance assays in HIV-1 patients, as a result there is a gap in 
data  about the drug resistance situation in these countries.  This thesis work was intended to 
evaluate drug resistance mutations in both drug naïve patients and in patients on ART so as to 
generate  resistance data that  will  reveal  the resistance situation in a HIV-1 cohort in a rural 
setting of Tanzania. 
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Although there are several commercially available methods for assaying HIV-1 drug resistance, 
antiretroviral  drug resistance assays  have largely been optimized based on HIV-1 subtype  B 
which is most prevalent sub-type in Western Europe, North America and Australia. In Tanzania, 
as in many other Sub-Saharan countries, the HIV-1 subtypes present are non-B sub-types. The 
standard genotyping method is sequencing which genotypes a single sample and requires 5-7 
sequencing reactions per sample. This makes it expensive to use in poor countries like Tanzania. 
This work intended to adapt and validate a microarray as an alternative technique for genotyping 
local  subtypes  present  in  Tanzania.  Microarray  technology  allows  simultaneous  analysis  of 
multiple SNPs through differential hybridization of target DNA to a library of oligonucleotide 
probes  arrayed  on  a  small  solid  surface  such  as  glass  [105].  A  microarray  platform  was 
previously developed at  Swiss  Tropical  and Public  Health  Institute,  Basel  (Swiss  TPH),  for 
detection  of  SNPs  in  drug  resistance  marker  genes  of  malaria  parasites  [106].  The  mini-
sequencing  principle  provides  highly  specific  base  calling,  while  the  hybridization  between 
panels of tags with reverse complementary anti-tags on the chip facilitate parallel genotyping of 
many SNPs at a time. The aim was to adapt this technique to genotyping SNPs in HIV-1. Such a 
tool would make it possible to genotype patient samples at relatively lower cost.  Due to relative 
low cost of microarray genotyping,  it  is logical  to make efforts  to use such a technology in 
resource poor countries like Tanzania. To minimize costs of microarray-based typing only those 
drug resistance mutations in the RT gene were targeted which are of relevance for antiretrovirals 
currently in Tanzania. The rather restricted selection of HIV drugs available in Tanzania limits 
the numbers of SNPs to be detected.  Development of such a genotyping tool could potentially 
provide  a  device  for  monitoring  HIV-1 drug resistance  in  resource  poor  settings.  Its  use  in 
molecular epidemiological studies and for surveillance will generate valuable data for decision 
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making on optimal and locally adapted treatment guidelines as well as for monitoring the spread 
of resistance.
1.16 THE STUDY SITE
This study was conducted in a HIV-1 cohort in Kilombero and Ulanga districts of Morogoro 
region in Tanzania.  This cohort was named KIULARCO. The cohort study was approved by 
ethics  review  bodies  of  Tanzania,  Ifakara  Health  Institute  (IHI)  institutional  review  board, 
National Institute for Medical Research, NIMR, and the Ethics Committee of the University and 
State of Basel, EKBB.  Patients were enrolled at the Chronic Disease Clinic of Ifakara, (CDCI), 
which serves as a Care and Treatment Centre for HIV/AIDS patients and is affiliated with the 
Ifakara Health Institute (IHI) and St Francis Referral Hospital (SFRH). The SFRH is the major 
health  facility  in  Kilombero  and Ulanga districts  and serves  a  population  of  about  600 000 
individuals. The first HIV-1 cases were reported in 1988 (M. Stoeckle, personal communication), 
five years later after the first HIV cases were found in Tanzania [92].  An estimated number of 
30 000 individuals have been infected with HIV-1 virus in these 2 districts [107]. As of October 
2011, the cumulative number of patients enrolled in CDCI was 5748, of which 3664 (63.7%) 
were females and 2084 (36.3%) were males and the number of people under ART was 3940 
(1395 males and 2545 females). 
1.17 AIMS AND OBJECTIVES
1.17.1 AIMS
This thesis work aimed at establishing the prevalence of HIV-1 drug resistance in drug naïve 
patients and patients under ART in a rural setting of Tanzania (KIULARCO cohort) as well as 
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adapting  and validating  a  low cost  genotyping  tool  (microarray)  for  monitoring  HIV-1 drug 
resistance in Tanzania. All genotyping procedures targeted specifically HIV subtypes present in 
Tanzania. The focus was on SNPs associated with RT resistance against first and second line 
drugs used in Tanzania. 
1.17.2 OBJECTIVES
To establish prevalence of drug resistance mutations in HIV-1 patients in KIULARCO 
cohort.
To optimize and validate an existing prototype genotyping chip for detection of SNPs in 
the RT gene.
1.17.2.1 SPECIFIC OBJECTIVES 
To sequence the RT and Protease genes of  baseline samples of KIULARCO patients in two time 
points; in 2005-2007 and 2009, so as to identify sequence diversity and estimate prevalence of 
mutations relevant for HIV-1 drug resistance. 
To asses development of drug resistance mutations after commencing ART in KIULARCO in 
2004. A follow up sample from the above patients were used. 
To investigate DR-mutations in all patients presenting with clinical, or immunological treatment 
failure in the period 2005-2009. 
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To  improve  a  prototype  microarray  for  detection  of  DR-SNPs  in  the  HIV-1  RT  gene  by 
optimizing all experimental steps.
To validate the HIV-DR-chip comparing microarray based typing with sequencing results from 
>100 KIULARCO patients.
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Chapter 2
Prevalence of Drug-Resistance Mutations and HIV-1 
Subtypes in a HIV-1 COHORT in rural Tanzania
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1.18 ABSTRACT 
1.18.1 Background 
The  development  of  resistance  mutations  in  drug-targeted  genes  compromises  success  of 
antiretroviral  therapy  (ART)  programmes.  Genotyping  of  these  mutations  enables  adjusted 
therapeutic  decisions  both  at  individual  and  population  level.  We  investigated  over  time 
prevalence of HIV-1 primary drug resistance mutations in treatment naive patients and described 
the HIV-1 subtype distribution in a cohort in rural Tanzania at the beginning of the ART roll out 
in 2005 and later in 2009.
1.18.2 Methods
Viral  RNA was reverse transcribed from 387 baseline plasma samples  from treatment  naïve 
patients over a period of five years. The reverse transcriptase (RT) and protease genes were PCR 
amplified  and  directly  sequenced  to  identify  the  HIV-1  subtypes  and  single  nucleotide 
polymorphisms associated with drug resistance (DR-SNPs). 
1.18.3 Results
The major  DR-SNPs in  2005 in the  RT gene were  K103N (5.0%),  Y181C (2.5%),  M184V 
(2.5%), G190A (1.7%) and M41L, K65KR, K70KR and L74LV (0.8%). In 2009 only K103N 
(3.3%), M184V and T215FY (0.8%) were detected. Initial frequencies of subtypes C, A, D and 
CRF01_AE were 37%, 28%, 24% and 11%, respectively. Later similar frequencies were found 
except  for  the  rare  observation  of  two  additional  subtypes,  B  and  F,  highlighting  subtype 
diversity and stable subtype frequency in the area.
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1.18.4 Conclusion
DR-SNPs were found at initiation of the cohort despite very low previous ART use in the area. 
Statistically  frequencies  of  major  mutations  did  not  change  significantly  over  the  five  year 
interval we studied. These mutations could reflect primary resistance and indicate a possible risk 
for treatment failure.
1.19 INTRODUCTION
Although  it  is  universally  recognised  that  combined  antiretroviral  therapy  (ART)  has 
dramatically reduced HIV-related mortality [1] [2], there are still some controversies by HIV-1 
experts over the benefits of wide scale use of these drugs in resource poor settings in terms of 
controlling morbidity and mortality on one hand and minimizing emergence and transmission of 
resistance strains on the other hand. One major concern raised by one group is that the rapid and 
not appropriately controlled scaling up of ART, may accelerate the selection of drug resistance 
mutations and transmission of HIV drug resistant strains in the population.  This could impair 
basic ART programmes as well as strategies to reduce HIV morbidity and mortality [3]. In view 
of the above, we aimed at investigating key resistance mutations in the reverse transcriptase (RT) 
and protease genes following ART rollout in a rural setting in Ifakara Tanzania.
In Tanzania, HIV prevalence in 2009 in adults 15-49 years of age was estimated to be 5.7%, 
corresponding to  1.5 million people,  of whom 6.6% were women and 4.6% were men.  The 
National  ART programme  started  in  2004  [4].  The  default  first  line  drugs  in  Tanzania  are 
Zidovudine/Stavudine,  Lamivudine  and  Nevirapine/Efavirenz  and  the  second  line  drugs  are 
Abacavir,  Didanosine  and  Lopinavir/Ritonavir  or  Indinavir/Ritonavir.  In  2009  more  than 
454,000 Tanzanian HIV-1 patients were in need of ART (according to the 2002 WHO criteria of 
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initiation of ART) and about 235,000 received ART [5]. However, according to more recent, 
2010 WHO criteria for initiation of ART [6], only one third of eligible patients in Tanzania are 
actually on ART. With many stakeholders supporting ART in the country, the Ministry of Health 
and Social Welfare (MoHSW) of Tanzania plans to further expand the ART coverage through its 
National Aids Control Programme (NACP).
In  late  2004  a  HIV  cohort  was  established  in  Morogoro,  rural  Tanzania.  The  aim  of  this  
Kilombero-Ulanga- Antiretro-viral-Cohort (KIULARCO) was to implement care and treatment 
of  HIV/AIDS  patients  according  to  the  Tanzania  National  AIDS  Control  Care  Programme 
(NACP) guidelines, to strengthen infrastructure, provide education of staff, to conduct research 
on  optimal  strategies  for  delivering  treatment,  and  to  conduct  follow-up  care  in  a  resource 
limited and rural setting in Tanzania [4] [7].
 To date, a total of 5748 HIV infected individuals have been enrolled at the CDCI. After a patient 
is enrolled, biomedical data are collected longitudinally. Blood samples are routinely collected at 
enrolment, before initiation of ART, and at different time points during visits to the clinic. In 
patients  under ART clinical  or immunological  parameters  are  assessed at  some point  during 
follow  up  visits.  Details  on  population  and  structure  of  the  KIULARCO cohort  have  been 
described previously [7] [8]. 
The term “primary HIV-1 drug resistance” defines a new infection with a resistant virus strain. 
The  presence  of  single  nucleotide  polymorphism associated  with  drug  resistance  (DR-SNP) 
plays  an important role in treatment outcome.  To investigate  primary drug resistance,  HIV-1 
isolates  from drug naive  persons are  examined  in a  cross  sectional  survey conducted  at  the 
beginning of the ART roll out in the cohort. A comparative analysis with samples collected in 
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subsequent years generally makes it possible to examine whether the level of primary resistance 
is  increasing  over  time  as  a  consequence  of  increased  drug  pressure  in  the  study area.  An 
increased level of primary resistance has been reported from other African countries, e.g. Nigeria 
[9].  Molecular monitoring of the prevalence of DR-mutations allows surveillance of transmitted 
resistance and may provide a valuable public health tool required in making decisions regarding 
HIV-1 treatment. 
Studies on the transmission of primary HIV-1 drug resistance in Tanzania are few and limited to 
urban areas  with large  HIV-1 sentinel  centres,  e.g.  Mbeya,  Kagera,  Kilimanjaro  and Dar es 
Salaam [10]  [11].  Additional  data  from the  situation  in  rural  areas  are  needed,  as  80% of 
Tanzanians  live outside urban centres.  Thus completed  surveillance  data  will  add to  a more 
precise and reliable picture of the HIV drug resistance situation in Tanzania. 
The genetic diversity among HIV-1 subtypes is extensive. The median percentage of amino acid 
differences within a subtype from the Los Alamos database was found to be 17% in Env and 8% 
in Gag, whereas the inter-subtype differences were 25% and 17%, respectively [13]. In contrast 
to  the  highly  variable  Env,  the  pol  sequence  is  more  conserved [12]  [13].  Different  HIV-1 
subtypes exhibit differences in the chance and routes of virus transmission, pathogenesis of the 
disease  as  well  as  in  the  kinetics  and  mechanisms  of  drug  resistance  development,  thus 
potentially affecting HIV-1 disease management [3] [14] [15]. 
This study aimed to investigate the prevalence of HIV-1 drug resistance mutations in treatment 
naive patients and to establish HIV-1 subtypes in the KIULARCO Cohort in Ifakara Tanzania 
between 2005-7 and 2009. 
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1.20 Materials and Methods 
1.20.1 Study Site and Subjects
The  KIULARCO study  was  approved  by  ethics  review  bodies  of  Tanzania,  Ifakara  Health 
Institute (IHI) institutional review board, National Institute for Medical Research, NIMR, and the 
Ethics Committee of the University and State of Basel, EKBB.  Patients were enrolled at the 
Chronic Disease Clinic of Ifakara, (CDCI) which serves as a Care and Treatment Centre for 
HIV/AIDS  patients  and  is  affiliated  with  the  Ifakara  Health  Institute  (IHI)  and  St  Francis 
Referral Hospital (SFRH). The SFRH is an important health facility in Kilombero and ulanga 
districts in Morogoro, South East Tanzania and serves a population of about 600 000 individuals. 
The first HIV-1 cases were reported in 1983 (Marcel Stoeckle personal communication) in a 
period  similar  to  first  HIV  cases  in  Tanzania  [4].   It  is  estimated  that  more  than  30  000 
individuals have been affected in the area [7]. By July 2008, a total of 2394 patients had been 
enrolled in the CDCI [7] [8]. As of October 2011, the cumulative number of patients enrolled in 
the CDCI was 5748 of which 3664 (63.7%) were females and 2084 (36.3%) were males.
Depending on their CD4 counts and HIV-1 WHO clinical staging, participants either received 
ART (CD4 counts ≤200 cells/µL regardless of WHO stage, CD4 counts ≤350 cells/µL and WHO 
clinical stage 3, or WHO stage 4 regardless of CD4 cell  count) or continued to be regularly 
followed up every three months. Before ART initiation, patient blood was drawn and plasma 
prepared  and  stored  at  -80°C.  Data  on  clinical,  virological,  immunological  parameters  and 
demographic data of patient samples (i.e. CD4 count, full blood picture, viral load, WHO clinical 
staging at enrolment, age, sex and home town or village) were collected.  
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A total of 187 plasma samples from the time period 2005-2007 were randomly selected from all 
baseline samples collected just before initiation of ART. Of those samples 137 were derived 
from patients starting ART immediately after this test sample was collected.  Fifty additional 
samples were chosen from HIV-1 infected patients with WHO clinical stage 3 and 4, who were 
not starting ART immediately. A second survey was conducted with 200 patients enrolled in the 
cohort in 2009. The 2009 inclusion criteria were: HIV-1 positive patients, age >18 years, with 
recent CD4 counts >250 cells/µL (WHO clinical stage 1 and 2) or >350 cells/µL (WHO clinical 
stage 3). All plasma aliquots were sent to Basel, Switzerland, for molecular genotyping. 
1.20.2 RNA extraction, RT-PCR, PCR and Sequencing   
Viral RNA was extracted from plasma with either the QIAamp Viral RNA Mini Kit (Qiagen, 
Hilden, Germany) or Macherey-Nagel NucleoSpin RNA Virus Kit (Macherey-Nagel GmbH & 
Co KG, Neumann-Neander, Germany) using the manufacturer’s protocol. 
Reverse transcription (RT) was performed using specific primer RT2  [32], AffinityScript RT 
Buffer  (500 mM TrisHCl  pH 8.3,  750 mM KCl,  30  mM MgCl2),  2  µL of  100  mM  DTT 
(Stratagene, North Torrey Pines Road La Jolla, CA), 0.8 µL dNTP mix (25 mM each dNTP), 1 
µL of  a  RNase Inhibitor,  RNase  Out  (40 U/µL),  1  µL AffinityScript  Multiple  Temperature 
Reverse  Transcriptase,  1  µL  specific  Primer  RT2  (5’-
GATAAGCTTGGGCCTTATCTATTCCAT-3`), (10µM), HPLC purified, and 9.5  µL  RNA 
solution. RT was performed with the following thermal conditions: 42°C for 35 min, 55°C for 25 
min, 70°C for 15 min and 5°C for 15 minutes. 
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Primary PCR (pPCR) was done using Advantage cDNA Polymerase according to the supplier’s 
protocol (Clontech Laboratories, Inc.Mountain, View, USA) with some modifications.  Reverse 
and forward primers  RT2 and D1818 (5’-AGAAGAAATGATGACAGCATGTCAGGGAGT-
3`) were used. The pPCR mix contained 5 µL 10x Advantage buffer (Clontech), 10 µL dNTP 
mix (2 mM), 2 µL reverse primer RT2 (10 µM),  2 µL forward primer D1818 (10 µM), 1 µL 
Advantage Polymerase (5U/µL) and 4 µL of cDNA. Reaction profile was 94°C for 2 min, 94°C 
for 20 sec, 47 °C for 20 sec, 68 °C for 2 min, 30 cycles and a final elongation step 68°C for  5 min 
were performed. 
Nested PCR (nPCR) mix for amplification of the HIV-1 reverse transcriptase gene was 5 µL 10x 
Pfu buffer (Promega Corporation, Woods Hollow Road, Madison, WI USA), 10 µL dNTP mix 
(2 mM), 2 µL forward primer JG103 5`-AACAATggCCATTgACAgAA[I-Q]-3` (10 µM), 2 µL 
reverse  primer JG202  5`-TCAggATggAgTTCATAICCCA-3`  (10  µM),  0.7  µL  FIREPol 
Polymerase (3U/µL), 0.1 µL Pfu Polymerase (3U/µL) and 2 µL pPCR product. Thermocyling 
conditions were: 94°C for 2 min, followed by 30 cycles of 94°C for 15 sec, 47°C for 15 sec, 72 °C 
for 2 min and a final elongation step 72°C for 5 min. PCR conditions for amplification of the 
protease gene were the same as for the RT gene except that a different primer set was used: 
forward primer D2213A2 (5’-AGCAGGATCCGAAAGACAGGGA-3’), (10 µM), and 
reverse primer R2598L (5’-CCATCCCGGGCTTTAATTTTACTGG-3’), (10 µM),. The nPCR 
products  were  purified  with  NucleoSpin  Extract  II  kit  (Macherey-Nagel)  according  to  the 
manufacturer’s protocol. 
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Direct  sequencing  of  purified  nPCR  products  was  performed  either  in  house  or  by  the 
commercial supplier, Macrogen, South Korea. The in house protocol used either of the forward 
primers  JG103  or  PMF  (5’-AACTCAAGACTTTTGGGAAGT-3’)  or  either  of  the  reverse 
primers JG202 or PMR (5’-TTGTCATGCTACTCTGGAATA-3’). PMF and PMR are centrally 
located sequencing primers for the RT gene. For nested PCR amplification and sequencing of the 
protease gene, the reagents and protocol used were the same as above with the exception that  
forward primer D2213A2 and reverse primer R2598L were used instead of RT-specific nested 
primers.  The sequences  obtained for each sample  were aligned using the Seqscape Software 
Programme  Version  2.6  (AB,  Applied  Biosystems,  Foster  City,  CA,  USA).  The  consensus 
sequences were assessed for drug resistance mutations by using the Stanford University HIV 
Drug Resistance Database HIVdb programme. The information on the HIV-1 subtype was also 
obtained from this database.
1.20.3 Viral Load Determination
Viral load was determined with a StepOne Real-Time PCR System (Applied Biosystems) by 
using a modification of the manufacturer`s instruction. cDNA was synthesized as shown above, 
but using random primers (0.1µg/µL). The cDNA was then quantified in qRT-PCR. The qRT-
PCR reaction contained 12.5 µL TaqMan® Gene Expression Master Mix, 0.125 µL forward 
primer M2227F, 5’-AGC CTC AAT AAA GCT TGC CTT G-3’ (10 µM), 0.125 µL reverse 
primer M2228R, 5’-CGG GCG CCA CTG CTA G-3’ (10µM), 0.5 µL probe HIV-FAM/BHQ, 
with FAM as a reporter dye located at the 5 prime end  and a black hole quencher at the 3 prime  
end, 5’-TGC CCG TCT GTT GTG TGA CTC TGG TAA-3’, (10µM), 5 µL cDNA and RNase 
free water to a final 25 µL reaction volume. qRT-PCR thermocycling conditions were as follows: 
Incubation (500C, 2min), initial denaturation (950C, 10min) and 44 cycles of denaturation (950C, 
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30sec) and annealing and extension (600C, 1min). Quantitation of cDNA was done relative to 
triplicate standard curves generated in each run from serial dilutions of a plasmid containing a 
viral DNA insert. Three no template controls were included for each run.
1.20.4 CD4+ T-Cell Counts
Single  platform  technique  (SPT)  was  used  to  enumerate  CD4+  T-helper  cells  using  BD 
TruCount® tubes (BD Biosciences, San Jose, California, USA). 50 µL of EDTA whole blood 
was stained using 5 µL monoclonal antibody mixture BD TriTEST™ CD3-FITC/CD4-PE/CD8-
PerCP (BD Biosciences) followed by 450 µL 1x BD lysis and fixative solution. Data acquisition 
and analysis by MultiTEST software was performed using 3 colors BD FACS Calibur (Becton 
Dickinson Immunocytometry Systems 2350). 
1.21 RESULTS
1.21.1 Baseline characteristics
The  clinical  and  demographic  characteristics  of  the  119  patients  from  2005-2007  and  120 
patients from 2009 were summarised in Table 2-7 and Table 2-8. The median age was 35 years 
in 2005-2007 and 40 years in 2009. Percentage of female study participants was 68.4 in 2005-
2007 and 62.3 in 2009. The median absolute CD4 cell count was 224 cells/µL and median viral 
load was 53020 copies/ml in 2005-2007 while in 2009 the median absolute CD4 cell count was 
420 cells/µL and the median viral load was 39920 copies/mL.
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1.21.2 Prevalence of HIV-1 Subtypes
The HIV-1 subtype was determined for each isolate based on the reverse transcriptase (codon 23 
to 236) and protease gene (codon 1 to 99) sequences. Subtypes frequencies are shown in Figure
2-10 for both study periods. Within the 119 samples analyzed in the years 2005-2007 HIV-1 
subtype C was most prevalent with a frequency of 37.3%. Other subtypes and their frequency of 
occurrence were A (28. %), D (24.0%) and CRF01_AE (10.7%). 
1.21.3 Prevalence of Anti-Retroviral Resistance Mutations
The major and minor drug resistance mutations in 2005-2007 and 2009 are shown in Table 2-5 
and Table 2-6 and Figure 2-11. The frequency of major reverse transcriptase inhibitors mutation 
in  2005-2007  was  8.4% and  in  2009  was  3.3%.  Whereas  the  NRTI  mutations  occurred  at 
frequency of 3.4% and 0.8%, that of NNRTIs occurred at frequency of 7.6% and 3.3% in 2005-
2007 and 2009, respectively. No major protease gene mutation was found in these two periods. 
1.22 DISCUSSION
The work at CDCI and subsequently KIULARCO cohort in rural Tanzania was initiated at the 
commencement of ART rollout in these two districts. Close clinical monitoring of patients was 
installed to guide treatment and switches of drug regimens. The comprehensive data gathered in 
the course of this rapidly growing cohort also provided a basis for epidemiological studies. A 
central question was to what extent the deployment of ART will drive the development of drug 
resistance under the specific conditions of a rural African setting. Like in other areas with limited 
resources, a number of typical shortfalls can lead to treatment failures, e.g. incomplete adherence 
to treatment or stock out of drugs at health institutions. Despite little previous availability of 
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ART in the study area, primary resistance, i.e. new infection by a drug resistant strain, must be 
expected to occur according to reports from other areas in Tanzania [10] [16] and could be a 
potential cause of treatment failures.  In Tanzania the prevention of mother to child transmission 
(PMTCT) of HIV-1 policy (2009) recommends combination regimens that include AZT, NVP 
and 3TC in areas with capacity to offer and monitor ART. For all other areas with no capacity to 
deliver ART, the policy recommends the use of minimum antiretroviral prophylaxis consisting of 
a single dose of nevirapine to the mother and the infant [17]. Particularly in Ifakara area, the use 
of  single  dose  nevirapine  for  PMTCT  was  noted  since  2004  (Marcel  Stoeckle  personal 
communication). This kind of a policy may contribute to development of resistance to nevirapine 
in the individuals and hence transmission of the resistant strains [18]. 
In the course of the first years of KIULARCO, treatment failures were observed. This prompted 
our investigation of transmission of primary resistance in the study area. In an attempt to gather 
baseline data for molecular epidemiological studies on drug resistant HIV-1 infections among 
KIULARCO patients, we compiled two molecular data sets, one describing the HIV-1 diversity 
and subtypes in the study area,  the other providing prevalence of DR-mutations in treatment 
naïve patients.  Because prior to ART rollout transmission of resistant  strains likely is a rare 
event, we expected to find very few DR-mutations in treatment naïve individuals. 
HIV-1 subtypes  C,  A,  D and CRF01_AE were  the  most  frequent  ones  among KIULARCO 
participants. Despite slight differences in the proportion of these subtypes and a presence of a 
single sample of subtype F, this distribution is in line with other reports from different parts of 
Tanzania  [1].  In  studies  conducted  in  the  Dar  es  Salaam,  Kilimanjaro,  Kagera  and  Mbeya 
regions, subtypes A and C were found to be the predominant HIV-1 subtypes [11] [19]. Our 
finding of a higher proportion of subtype C in Ifakara is plausible, since Ifakara is linked by 
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railway to Zambia, where subtype C prevails [20]. Subtype B was not detected in the 2005-2007 
samples, and was found in six cases (5%) in samples from 2009. Although subtype B is rare in 
Africa, it has been reported previously from Kilimanjaro, Tanzania [21]. A possible explanation 
for the detection of subtype B in KIULARCO could be transmissions  from individuals with 
exposure to Western Countries. Subtype F, which was observed in one single sample in 2009, 
has been reported in Europe,  South America  and in Central  Africa [22] [23].  Therefore this 
subtype  might have been brought to Tanzania from neighbouring West-Central  Africa where 
reports of subtype F occurrence exist [22] [24].
A  limitation  of  our  subtype  analysis  is  that  it  was  limited  to  HIV-1  protease  and  reverse 
transcriptase.  The sequence  data  generated  for  these  two regions  might  not  capture  the  full 
diversity and may underestimate some of the recombinant forms [11]. The analysis is, however, 
representative in the context of other studies as the  pol region has been used previously for 
subtyping  HIV-1  [1]  [19].  This  approach  represents  a  straight-forward  way  of  identifying 
circulating HIV-1 subtypes in population studies, especially in resource-poor settings.
Our findings highlight the diversity of HIV-1 subtypes in rural Tanzania and contribute further 
data  points  to  a  countrywide  picture  of  subtype  frequencies.  The  longitudinal  comparison 
indicates stable subtype frequencies over a period of at least four years with minor changes as 
well as the new appearance of isolates of subtypes B and one single isolate of subtype F in 2009. 
We  compared  the  prevalence  of  DR-mutations  in  drug  naive  patients  from  two  surveys, 
conducted  in  2005-2007  and  2009.  The  rationale  for  this  molecular-epidemiological 
investigation was to identify potential effects of ART roll out on prevalence of DR-mutations.  
The two sampling  periods  represented  were chosen at  the  beginning of  the  Tanzanian  ART 
47
Prevalence of Drug-Resistance Mutations and HIV-1 Subtypes in a HIV-1 COHORT in Rural Tanzania
programme (2004) and 5 years after initiation.  We assumed that the effects of drug pressure 
might lead to a first visible increase in transmitted resistance mutations in the population during 
subsequent years. 
In data analysis we first assessed comparability of our sets of samples because the mean time to 
ART  initiation  differed  between  the  sets.  Prevalence  of  DR-mutations  in  75  samples  with 
immediate  ART initiation  was  compared  with  44  samples  in  2005-2007 with  delayed  ART 
initiation. We also compared WHO stage, age, sex, subtypes, means of CD4 counts and viral 
load values.  Among all the parameters tested, only the higher age was of significance (95% 
Confidence  interval,  0.5-9.5)  in  samples  with  delayed  start  of  ART.  Since  there  were  no 
significant differences in DR-mutations and other factors compared between subsets of samples 
with  early  versus  late  treatment  start  (Table  2-9:  Supplementary  Table  S1  and  Table  2-10: 
Supplementary Table S2), all 2005-2007 samples were pooled for comparative analysis with the 
2009 data set. We concluded that variation in time to ART initiation did not lead to a sampling  
bias. 
Our results indicated that the prevalence of major reverse transcriptase mutations was 8.4% in 
2005-2007 and 3.3% in  2009.  This  difference  in  prevalence  was not  statistically  significant 
(p=0.1069). The prevalence rates of non-nucleoside reverse transcriptase mutations were 3.4% in 
2005-2007 and 0.8% in 2009, respectively, (P=0.2128). Although the differences in prevalence 
of RTI mutations were not stastistically significant different, the higher number DR-mutations in 
2005/7 might be attributed to a higher number of patients in WHO clinical stage 3 and 4 (Table
2-7)  and  differences  in  the  CD4  in  these  two  periods  (Table  2-8).  Patients  enrolled  in 
KIULARCO are routinely monitored for CD4 counts and clinical progression. A threshold value 
of 200 CD4 cells/µL and WHO clinical stages 3 and 4 are currently used by clinicians as criteria  
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for ART initiation. The observed difference in CD4 counts between the compared sets of patients 
might be attributed to the fact that people in the community became more aware of the HIV-
1/AIDS health care services offered by the cohort, so they attended the clinic at earlier stages of 
the disease than previously. Differences in the average CD4 counts in the two periods could have 
influenced the outcome of our comparisons.  Individuals  in 2005-2007 had lower CD4 count 
values (275 cells/µL) compared to individuals in 2009 (531 cells/µL), which could indicate that 
the former group had a weaker immunological control, thus permitting higher viral replication 
rates and more chances for mutations to arise. But the finding of similar viral load between both 
sets of patients does not support this explanation. A possible explanation for the lower viral load 
in 2005-2007 samples might be due to prolonged and poor storage (frequent interruptions in 
electricity at time of Cohort initiation) condition of samples at Ifakara (Edith Horvath personal 
communication)  which  could  have  led  to  deterioration  of  RNA  before  their  shipment  to 
Switzerland for virological count and genotypic assays.
The NNRTI mutations K103N, Y181C and G190A cause high-level resistance to nevirapine, one 
of the two common NNRTI drugs used in Ifakara and elsewhere in Tanzania [25] [26].  All 
individuals with DR-mutations in 2009 and 60% of individuals in 2005-2007 carried the K103N 
mutation. This high prevalence of the K103N mutation may be due to prior use of Nevirapine 
monotherapy for PMTCT in Tanzania [17]. The prior presence of this mutation in a patient likely 
influences  the outcome of ART by conveying a  selective  advantage  and a  head start  in  the 
accumulation of DR-mutations and their rapid selection under drug pressure. KIULARCO and 
other Tanzanian ART programmes can offer only few treatment options [26]. The observed level 
of primary resistance must be considered as a potential threat to the efficiency of the Tanzanian 
ART programme [18] [27]. 
49
Prevalence of Drug-Resistance Mutations and HIV-1 Subtypes in a HIV-1 COHORT in Rural Tanzania
In summary, DR-mutations were present in drug naive patients at both time points compared. 
Contrary to our expectation, we did not find significant differences in the frequency of resistance 
mutations between 2005-2007 and 2009, but we identified a trend suggesting higher mutation 
frequencies  in  samples  collected  earlier  in the cohort.  Minor  differences  in  the repertoire  of 
mutations were observed, most likely reflecting a chance finding owing to the small sample size. 
The number of KIULARCO patients under ART in the middle of our sampling period was 1,491 
(December 2008) [7]. These numbers might be too small to provoke a measurable increase in 
transmitted resistance mutations within four years. 
Overall our findings from both years are in agreement with genotypic results from other studies 
in Tanzania and elsewhere in Africa, which also indicated that primary drug resistance mutations 
are present in treatment naive patients even before the scale up of ART  [10] [16]. 
1.23 CONCLUSION
Our molecular typing provides the first baseline information on HIV-1 strains encountered in a 
rural area in Southern Tanzania. Our data support a relatively stable subtype distribution with 
limited influx of new strains and a low prevalence of pre-existing drug resistance mutations as 
low potential threat for the ongoing ART-rollout. Demonstration of the extent and significance of 
HIV-1 drug resistance mutations in treatment naive individuals is useful for an informed choice 
of ART and thus can contribute to efforts towards preventing the spread of drug resistance. 
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Table 2-5: Major HIV-1 drug resistance mutations in treatment naïve Ifakarara patients in 
2005-2007 and 2009.
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Patient 
ID
Subtype Major DR-mutations Sex Age (yrs)
2005-7
5410033 D K103N F 42
5510060 D M41L F 40
5510135 C K103N M 47
5510184 CRF01_AE M184V,G190A F 29
5510187 C K103N, Y181C F 4
5510259 C K103N F 30
5511494 C K103N F 30
5510599 C Y181C F 51
5510039 A M184V, G190A F 31
5510072 C
K65KR, K70KR, 
L74LV, M184V, 
K103N, Y181C
F 45
2009
5514370 A
K103N, M184V, 
T215F
F 63
5421041 CRF01_AE K103N - -
5513670 C K103N M 35
5511139 C K103N M 4
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DR-SNPs; drug-resistance single nucleotide polymorphisms
Table  2-6: Frequency of  observation of  HIV-1 DR-Mutations in KIULARCO cohort in 
2005-7 and 2009
DR-SNP 2005-7 (n = 119) 2009 (n = 120)
Frequency (%) Frequency (%)
Major NRTI 
Mutations
M41L 1(0.8) -
K65KR 1(0.8) -
K70KR 1(0.8) -
L74LV 1(0.8) -
M184V 2(1.6) 1(0.8)
M184MV 1(0.8) -
T215F - 1(0.8)
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Subtotal: major NRTI 7(5.9) 2(1.7)
NNRTI 
Mutations
K103N 6(5.0) 4(3.3)
Y181C 3(2.5) -
G190A 2(1.7) -
Subtotal: major NNRTI 11(9.2) 4(3.3)
Total major RT Mutations
18(15.1) 6(5.0)
Minor NRTI 
Mutations
M41KM 1(0.8) -
D67G - 1(0.8)
D69S 1(0.8) -
V118I - 3(2.5)
H221HY 1(0.8) -
Subtotal: minor NRTI 3(2.5) 4(3.3)
NNRTI 
Mutations
V90I - 1(0.8)
V108I - 1(0.8)
V179D - 1(0.8)
G190R 1(0.8) -
Subtotal: minor NNRTI 1(0.8) 3(2.5)
All Minor Mutations in RT 4(3.4) 7(5.8)
Minor 
Protease 
Mutations
L33FL - 1(0.8)
L10V 9(7.6) 1(0.8)
L10I 4(3.4) 1(0.8)
L10IL - 1(0.8)
L10IV 1(0.8)
V11I 2(1.7) -
V11IV - 1(0.8)
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L23F 1(0.8) -
A71T 1(0.8) -
T74S 1(0.8) -
L89V - 1(0.8)
Total : Minor Protease Mutations 18(15.1) 7(5.8)
DR-SNPs, drug-resistance single nucleotide polymorphisms; RT, Reverse-transcriptase; NRTI, 
Nucleoside reverse-transcripatse inhibitor; NNRTI, Non-nucleoside reverse-transcripatse 
inhibitor.
Table 2-7: Comparison of baseline categorical characteristics of KIULARCO patients in 
2005-7 and 2009.  
     years 2005-7 year 2009 Difference in 
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WHO Stage (n = 116) (n = 118)
1 39 0.336 ± 0.086 60 0.508 ±0.090
0.048 - 0.297*
(p =0.0084)
2 22 0.190 ± 0.071 35 0.297 ± 0.082
-0.002 - 0.216
(p =0.0678)
3 35 0.302 ± 0.084 21 0.169 ± 0.068
0.015 - 0.232*
(p= 0.0319)
4 20 0.172 ± 0.069 3 0.025 ± 0.028
0.073 - 0.221*
(p = 0.0001)
Sex (n = 117) (n = 118)
Females 80 0.684 ± 0.084 74 0.627 ± 0.087
-0.065 - 0.178
(p = 0.4108)
Males 37 0.316 ± 0.084 44 0.373 ± 0.087 -0.178 - 0.065
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(p = 0.4108)
DR-
Mutations
(n = 119) (n = 120)
Major RTIs 10 0.084 ± 0.050 4 0.033 ± 0.032
-0.009 - 0.110
(p =0.1069)
Major 
NRTIs
4 0.034 ± 0.033 1 0.008 ± 0.016
-0.011 - 0.062
(p = 0.2128)
Major 
NNRTIs
9 0.076 ± 0.048 4 0.033 ± 0.032
-0.015 - 0.100
(p = 0.1666)
Minor RTIs 3 0.025 ± 0.028 6 0.050 ± 0.039
-0.023 -0.073
(p = 0.4994)
Minor PIs 16 0.134 ± 0.061 7 0.058 ± 0.042
0.002 - 0.150
(p = 0.0509)
Subtypes (n = 119) (n = 120
A 31 0.280 ± 0.079 29 0.242 ± 0.077
-0.091- 0.129
(p =0.7670)
C 52 0.373 ± 0.089 54 0.450 ± 0.089
-0.113 - 0.139
(p =0.8966)
CRF01_AE 11 0.107 ± 0.052 9 0.075 ± 0.047
-0.053 - 0.088
(p =0.6487)
D 28 0.240 ± 0.073 21 0.175 ± 0.068
-0.065 - 0.135
(p =0.2658)
B - - - 6 0.050 ± 0.039 (p =0.0293)*
F - - - 1 0.008 ± 0.016 (p =1.0000)
DR mutation, drug resistance mutation; NRTIs, Nucleoside reverse-transcripatse inhibitors; 
NNRTIs, Non-nucleoside reverse-transcripatse inhibitors; PIs, Protease inhibitors
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*The difference is statistically significant 
Table 2-8: Comparison of baseline numeric characteristics in 2005-7 and 2009 in 
KIULARCO patients
2005-7 2009 Difference in Means
95% CI 95% CI
95% CI of 
Difference (p)
CD4 counts
(cells/µL)
(n = 116) (n = 117)
Mean 278 278 ± 44 456 456 ± 51
111 – 245*
(p = 0.0088)
Viral Load
(copies/ml)
(n = 92) (n = 112)
Mean 122 599
122 599 ±
43 246
287 217
287 217 ±
95 683
51 967 - 277 269*
(p = 0.0046)
Age (Years) (n = 116) (n = 118)
Mean/Median 37 37± 2 42 42 ± 2
2 – 8*
(p =0.0006)
* The difference is statistically significant 
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Table 2-9: Supplementary Table S1: Comparison of baseline characteristics of treatment 
naive KIULARCO patients with immediate initiation of ART versus patients with ART 
initiation at a later date in 2005-7. 
  Immediate initiation of 
ART 
Initiation of ART at a later 
date
Difference in 
Proportion
Fr
eq
ue
nc
y 
 
Pr
op
or
tio
n
95
%
 C
I 
Fr
eq
ue
nc
y 
Pr
op
or
tio
n
95
%
 C
I
95
%
 C
I o
f 
D
iff
er
en
ce
 (p
)
WHO Stage (n = 75) (n = 41)
1 25 0.333 ± 0.107 14 0.341 ± 0.145 -0.172 - 0.188
(p =1.0000)
2 14 0.187 ± 0.088 8 0.195 ± 0.121 -0.142 - 0.158
(p = 1.0000)
3 23 0.307 ± 0.104 12 0.293 ± 0.103 -0.160– 0.188
(p = 1.0000)
4 13 0.173 ± 0.115 7 0.171 ± 0.086 -0.141– 0.146
(p = 1.0000)
Sex (n = 75) (n = 42)
Females 53 0.707 ± 0.103 27 0.643 ± 0.145 -0.114 - 0.242
(p = 0.5364)
Males 22 0.293 ± 0.103 15 0.357 ± 0.145 -0.242 - 0.114
(p = 0.5364)
DR-Mutation (n = 75) (n = 44)
Major RTIs 6 0.080 ± 0.061 4 0.091 ± 0.085 -0.094 - 0.116
(p = 1.0000)
Major NRTIs 3 0.040 ± 0.044 1 0.023 ± 0.085 -0.045 - 0.080
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(p = 1.0000)
Major 
NNRTIs
5 0.067 ± 0.057 4 0.091 ± 0.085 -0.078 - 0.126
(p = 0.7243)
Minor RTIs 2 0.027 ± 0.037 - - - -(p = 0.5300)
Minor PRIs 11 0.147 ± 0.080 5 0.114 ± 0.094 -0.090 - 0.156
(p =0.7825)
Subtype (n = 75) (n = 44)
A 21 0.280 ± 0.102 10 0.227 ±0.124 -0.107 - 0.213
(p =0.6659)
C 28 0.373 ± 0.109 24 0.545 ± 0.147 -0.011 - 0.356
(p = 0.0855)
CRF01_AE 8 0.107 ± 0.070 3 0.068 ± 0.074 -0.064 - 0.141
(p = 0.7444)
D 18 0.240 ± 0.097 7 0.159 ± 0.108 -0.064 - 0.226
(p = 0.3562)
ART, antiretroviral therapy; DR-mutation, drug resistance mutation; NRTIs, Nucleoside reverse-
transcripatse inhibitors; NNRTIs, Non-nucleoside reverse-transcripatse inhibitors; PIs, Protease inhibitors 
Table 2-10: Supplementary Table S2: Characteristics of Numeric Variables for Patients 
with immediate and delayed ART Start in 2005-7 in Ifakara HIV-1 Cohort
Immediate ART Start Delayed ART Start Difference in 
Means
95% CI 95% CI 95% CI of 
Difference (p)
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CD4 counts
(cells/µL)
 
(n = 74) (n = 41)
Mean 303 303 ± 57 234 234 ± 67 -20 - 158
(p =0.1400)
Viral Load
(copies/ml)
(n = 57) (n = 35)
Mean 142 447 142 447 ± 
59 135
90 276 90 276 ± 
62 190
-30 030 - 
143 358
(p =0.2483)
Age (Years) (n = 69) (n = 36)
Mean 35 35 ± 13 40 40 ± 10 0.5 - 9.5*
(p =0.0396)
ART, antiretroviral therapy
* The difference is statistically significant
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Figure 2-10: Prevalence of HIV-1 Subtypes in Ifakara COHORT in 2005-2007 and 2009. 
Bar lines represent 95% confidence interval.
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Figure 2-11: Prevalence of HIV-1 DR mutations in 2005-7 and 2009 in Ifakara HIV-1 
Cohort. RTIs, reverse-transcriptase inhibitors; NRTIs, nucleoside reverse-transriptase inhibitors; 
NNRTIs, nonnucleoside reverse-transcriptase inhibitors; PIs, protease inhibitors. Bar lines 
represent 95% confidence
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1.26 ABSTRACT
1.26.1 Background 
In Tanzania antiretroviral therapy (ART) roll out started in 2004.  One of the main public health 
challenges is the emergence and spread of HIV-1 drug resistance. Molecular monitoring of drug 
resistance  mutations  in  patients  under  ART,  and  in  particular  in  cases  of  suspected  clinical 
resistance, may provide important epidemiological data regarding acquired resistance due to drug 
pressure  or  patient  adherence  to  treatment.  We  investigated  the  prevalence  of  resistance 
mutations in HIV-1 patients under treatment from the KIULARCO cohort in rural Tanzania. 
1.26.2 Methodology
Plasma samples from 137 randomly selected patients under ART for >6 months were analyzed. 
In addition we investigated all cases of suspected clinical resistance that were reported in this 
cohort between 2005 and 2009. Drug resistance (DR) associated mutations were identified by 
PCR and direct sequencing of the reverse transcriptase (RT) and protease genes.
1.26.3 Results
Amplicons were obtained only from 16/137 samples of randomly selected patients under ART. 
Major  mutations  conferring  resistance  to  RT  inhibitors  were  detected  in  2/16  (12.5  %) 
individuals  under  ART  and  in  6/17  (35.3%)  cases  of  suspected  clinical  resistance.  Minor 
mutations were detected in 7/16 (43.8 %) individuals under ART and in 6/17 (35.3%) cases of 
suspected resistance. In protease gene no major mutations were found in any group, but minor 
mutations occurred in 2/17 (11.8%) suspected resistance cases.
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1.26.4 Conclusion
The detected mutations among individuals under treatment pose a threat to ART outcomes in 
KIULARCO cohort. If these mutations are transmitted in the population, they may lead to an 
increase in prevalence of resistant viral strains in this area. Because only 35% of the suspected 
clinical  resistance  cases  carried  DR  mutations,  other  factors  must  have  contributed  to  the 
compromised ART response, e.g. non-adherence. Further studies are required to determine other 
major reasons for ART failure in rural Tanzania. 
1.27 INTRODUCTION
About 2.1 million people with HIV-1/AIDS were recorded in Tanzania resulting in a HIV-1 
prevalence of 6.5% by 2009 [1]. The Tanzanian antiretroviral treatment (ART) program started 
officially in 2004 [2]. By 2009,  235 092 (55.6%) out of the 422 632 eligible ART recipients 
received  treatment.  ART in  Tanzania  is  provided  by 563  care  and  treatment  clinics  (CTC) 
present throughout the country [1]. An HIV-1 treatment cohort was established in Ifakara, rural 
Tanzania,  in  late  2004.  This  cohort,  named  Kilombero-Ulanga  Cohort  (KIULARCO),  was 
among  the  first  centers  in  Tanzania  to  implement  this  program [3].  By October,  2011,  the 
cumulative number of patients enrolled in KIULARCO was 5748, and 3940 patients were on 
ART. 
Several studies in developing as well as developed countries have reported some resistance in 
patients receiving ART [4] [5] [6]. For example, Bannister et al., 2011, observed a prevalence of 
35%  drug  resistance  mutations  when  estimating  the  prevalence  of  accumulated  HIV  drug 
resistance in patients receiving antiretroviral therapy in a group of 6498 EuroSIDA patients who 
were under follow-up on ART in 2008 [4] .  
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Roll out of ART in Africa can be expected to also result in development and spread of drug 
resistance. Major reasons could be lack of funds, infrastructure and technical personnel in these 
countries threatening regular and uninterrupted procurement,  distribution,  and safe storage of 
antiretroviral drugs [6]. In view of an expected emergence of resistance to ART, surveillance of 
the  frequency  of  resistant  strains  appearing  in  patients  under  ART  can  provide  useful 
epidemiological information, e.g. on the risk of transmission of acquired resistance mutations or 
on mutation frequencies that will guide the choice of locally suitable first and second line ART 
regimen. 
In Tanzania, major demographic and socio-economic differences exist not only between urban 
and rural areas but also among different urban areas. A few studies conducted in urban areas of 
Tanzania  reported  varying  prevalence  rates  of  HIV-1  drug  resistance  (DR)  mutations  in 
treatment  naïve  individuals  [7]  [8]  [9].  Reports  on  DR  mutations  in  treatment-experienced 
individuals from Tanzania are rare. In a study by Nyombi and colleagues, carried out among 
women  who  had  received  a  single  dose  nevirapine  (sdNVP)  to  prevent  mother  to  child 
transmission (PMTCT) of HIV-1 in Kagera and Kilimanjaro regions in 2005, the prevalence of 
NNRTIs mutations was 1.6% and 11.5% in Kagera and Kilimanjaro, respectively [7]. Only one 
study so far has been conducted in individuals under treatment from Hydom in rural Tanzania, 
which showed a trend towards increasing prevalence of DR mutations following ART use [10].
In view of substantial differences in frequencies of DR mutations detected in different settings in 
Tanzania,  further investigations, particularly in rural areas, could reveal an even more severe 
picture  of  DR  due  to  infrastructural  problems  outside  the  reach  of  urban  health  facilities. 
Restricted  availability  of  ART could  enhance  emergence  of  drug  resistance  in  these  areas. 
Substantial differences in both, frequencies of DR mutations and haplotypes, may be found when 
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comparing urban and rural settings. We hypothesized that shortfalls in the distribution of ART 
and non-adherence to the prescribed treatment are more frequent in rural than in urban settings in 
Tanzania and, as a consequence, that the prevalence of acquired DR mutations would be higher 
in remote areas.
To test this hypothesis we carried out a genotypic analysis of HIV-1 virus from 137 randomly 
selected KIULARCO patients who had been on ART for at least six months in order to describe 
the prevalence of resistance mutations in the reverse transcriptase and protease genes. During the 
first 5 years of treatment and care for KIULARCO patients, 17 cases of suspected drug resistance 
were recorded. Viral  isolates from these patients  were also analyzed in order to identify DR 
mutations as possible causes of treatment failure. 
1.28 MATERIAL AND METHODS
1.28.1 Study Site and Subjects
The KIULARCO HIV cohort was established in 2004 in Kilombero and Ulanga districts,  in 
Morogoro region, southern Tanzania, for the dual purpose of implementing care and treatment of 
HIV/AIDS patients according to Tanzania National AIDS Control Care Programme (NACP) and 
to conduct research on essential minimal care for HIV patients in rural resource poor settings. 
Patients  were  enrolled  at  the  Chronic  Disease  Center  (CDC)  affiliated  with  Ifakara  Health 
Institute and St. Francis Referral  Hospital (SFRH), the latter being the main district hospital in 
the two districts providing treatment and care for a population of > 600,000. In this area 30,000 
people are leaving with HIV/AIDS [3]. 
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137 patients under treatment were randomly selected. They started ART after meeting CD4 and 
WHO stage criteria adopted by the Tanzanian NACP. The following criteria for ART initiation 
were applied: WHO clinical stage 4, CD4 count of <200 cells/µl, or WHO stage 3 with CD4 
count  <350  cells/µl. The  first  line  drug  combination  contained  Stavudine/Zidovudine  + 
Lamivudine  +  Nevirapine/Efavirenz,  the  second  line  consisted  of  Abacavir  +  Didanosine  + 
Ritonavir-boosted Lopinavir. Patients were monitored for their CD4 counts and HIV-1 WHO 
staging just before and 3 months after initiation of ART. Thereafter routine visits occurred every 
six months. Data on clinical, virological or immunological parameters of patient samples were 
collected and recorded. The data included: CD4 count and full blood picture, viral load, WHO 
stage, ART regimen, reason for ART initiation, changes of ART regimen and reasons for change, 
ART failure and reason for failure, adherence grade, and demographic data, such as sex, place of 
origin,  marital  status, and referral  sites.  This study was approved by ethics review bodies of 
Tanzania, Ifakara Health Institute (IHI) institutional review board, National Institute for Medical 
Research (NIMR), and the Ethics Committee of Canton Basel (EKBB). Patients taking part in 
this study have given their informed consent.
Plasma samples from 137 randomly selected individuals on ART were collected between 2005 
and 2007. Samples from the 17 patients with suspected resistance were obtained between 2005 
and 2009.
1.28.2 RNA extraction, RT-PCR, PCR and Sequencing
Viral RNA was extracted from plasma with either the QIAamp Viral RNA Mini Kit (Qiagen, 
Hilden, Germany) or Macherey-Nagel NucleoSpin RNA Virus Kit (Macherey-Nagel GmbH & 
Co KG, Neumann-Neander, Germany) using the manufacturer’s protocol. 
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Reverse transcription (RT) was performed using specific primer RT2, AffinityScript RT Buffer 
(500 mM TrisHCl pH 8.3, 750 mM KCl, 30 mM MgCl2), 2 μl of 100 mM DTT (Stratagene,  
North Torrey Pines Road La Jolla, CA), 0.8 μl dNTP mix (25 mM each dNTP), 1 μl of a RNase 
Inhibitor, RNase Out (40 U/µl), 1 μl AffinityScript Multiple Temperature Reverse Transcriptase, 
1 µl specific Primer RT2 (5’-GATAAGCTTGGGCCTTATCTATTCCAT-3`), (10 µM), HPLC 
purified, and 9.5 µl RNA solution. RT was performed with the following thermal conditions: 
42°C for 35 min, 55°C for 25 min, 70°C for 15 min and 5°C for 15 min. 
All  primers  used  in  this  work  were  synthesized  by    Eurofins  (Eurofins  MWG  Operon, 
Huntsville, Alabama 35805, USA.
Primary PCR (pPCR) was done using Advantage cDNA Polymerase according to the supplier’s 
protocol (Clontech Laboratories, Inc.Mountain, View, USA) with some modifications.  Reverse 
and forward primers  RT2 and D1818 (5’-AGAAGAAATGATGACAGCATGTCAGGGAGT-
3`) were used. The pPCR mix contained 5 µl 10x Advantage buffer (Clontech), 10 µl dNTP mix 
(2 mM), 2 µl reverse primer RT2 (10 µM),  2 µl forward primer D1818 (10 µM), 1 µl Advantage 
Polymerase (5U/µl) and 4 µl of cDNA. Reaction profile was 94°C for 2 min, 94°C for 20 sec, 
47°C for 20 sec, 68°C for 2 min, 30 cycles followed by a final elongation step at 68°C for 5 min. 
The nested PCR (nPCR) mix for amplification of the HIV-1 reverse transcriptase gene contained 
5 μl 10x Pfu buffer (Promega Corporation, Woods Hollow Road, Madison, WI USA), 10 μl 
dNTP mix (2 mM), 2 μl forward primer JG103 5`-AACAATGGCCATTGACAGAA[I-Q]-3` (10 
µM),  2  μl  reverse  primer JG202  5`-TCAGGATGGAGTTCATAICCCA-3`  (10  µM),  0.7  μl 
FIREPol  Polymerase  (3U/µl),  0.1  μl  Pfu  Polymerase  (3U/µl)  and  2  μl  pPCR  product. 
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Thermocyling conditions were: 94°C for 2 min, followed by 30 cycles of 94°C for 15 sec, 47°C 
for 15 sec, 72  °C for 2 min and a final elongation step at 72°C for 5 min. PCR conditions for 
amplification of the protease gene were the same as for the RT gene except  that a different 
primer set  was used: forward primer D2213A2 (5’-AGCAGGATCCGAAAGACAGGGA-3’), 
(10 µM), and reverse primer R2598L (5’-CCATCCCGGGCTTTAATTTTACTGG-3’), (10 
µM). nPCR products were purified with NucleoSpin Extract II kit (Macherey-Nagel GmbH & 
Co KG, Neumann-Neander, Germany) according to the manufacturer’s protocol. 
Direct sequencing of purified nPCR products was performed either in house using a Genetic 
analyser  3130  (Applied  Bisosystems,  Switzerland)  or  by  a  commercial  supplier,  Macrogen, 
South Korea. The in house protocol used either one of the two forward primers JG103 or PMF 
(5’-AACTCAAGACTTTTGGGAAGT-3’) or one of the two reverse primers JG202 or PMR (5’-
TTGTCATGCTACTCTGGAATA-3’).  PMF  and  PMR  were  centrally  located  sequencing 
primers for the RT gene. For nested PCR amplification and sequencing of the protease gene, the 
reagents  and protocol  used  were the same as  above with  the  exception  that  forward primer 
D2213A2 and reverse primer R2598L were used instead of RT specific  nested primers.  The 
sequences obtained for each sample were aligned using Seqscape Software Program Version 2.6 
(Applied Biosystems). The consensus sequences were assessed for drug resistance mutations by 
using the Stanford University HIV Drug Resistance Database HIVdb program. The information 
on the HIV-1 sub-type was also obtained from this data base.
1.28.3 Viral Load Determination
Viral load was determined with a StepOne Real-Time PCR System (Applied Biosystems,  Foster 
City, CA, USA) using a modification of the manufacturer`s instruction. cDNA was synthesized 
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as shown above, but using random primers  (Eurofins MWG Operon) (0.1µg/µl). The cDNA was 
quantified by qRT-PCR. The qRT-PCR reaction contained 12.5 µl TaqMan® Gene Expression 
Master Mix, 0.125 µl forward primer M2227F, 5’-AGC CTC AAT AAA GCT TGC CTT G-3’ 
(10 µM), 0.125 µl reverse primer M2228R, 5’-CGG GCG CCA CTG CTA G-3’ (10µM), 0.5 µl 
probe HIV-FAM/BHQ, with FAM as a reporter dye located at the 5‘ end  and a black hole 
quencher at the 3‘ end ( 5’-TGC CCG TCT GTT GTG TGA CTC TGG TAA-3’; 10µM), 5 µl 
cDNA and RNase free water to a final 25 µl reaction volume. The qRT-PCR thermocycling 
conditions were as follows: incubation (50°C, 2 min), initial denaturation (95°C, 10min) and 44 
cycles of denaturation (95°C, 30 sec) and annealing and extension (60°C, 1min). Quantitation of 
cDNA was done relative to triplicate standard curves generated in each run from serial dilutions 
of a plasmid containing a viral DNA insert. Three no template controls were included in each 
run.
1.28.4 CD4 Counts
A single platform technique was used to enumerate CD4+ T-helper cells using BD TruCount® 
tubes (Becton Dickinson Biosciences, San Jose, California, USA). 50 µl of EDTA whole blood 
was stained using 5 µl monoclonal antibody mixture BD TriTEST™ CD3-FITC/CD4-PE/CD8-
PerCP followed by 450 µl 1x BD lysis and fixative solution. Data acquisition and analysis by 
MultiTEST software was performed using 3 colors BD FACS Calibur. 
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1.29 RESULTS
1.29.1 Characteristics of the Patients
Plasma samples from randomly selected 137 individuals on ART were analyzed, but only 16/137 
(11.7 %) samples could be amplified and sequenced. In contrast, all samples from 17 patients 
with  suspected  drug  resistance  were  successfully  amplified  and  sequenced.  The  baseline 
characteristics of the randomly selected group are shown in Table 3-11 while the characteristics 
of all patients with positive results (with positive viral PCR product and a viral sequence) are 
shown in Table 3-12. Among the patients randomly selected on ART 50% were female, whereas 
in the suspected resistance group 64% were women.  The mean CD4 count for patients under 
ART was 247 cells/µl after six months of ART usage, indicating that most of patients had CD4 
counts that were only slightly higher than recommended CD4 level requiring initiation of ART. 
We also measured CD4 counts in patients with suspected resistance at the time point of the first 
change of ART regimen. Mean CD4 count in this group was 76 cells/µl. Viral loads (VL) were 
determined  for  both  groups  of  patients.  Mean  VL in  the  group  of  randomly  selected  ART 
patients  was  124  022  copies/ml,  in  the  suspected  resistance  group  mean  VL was  317  955 
copies/ml. As expected, VL was higher in the cases of suspected resistance than in randomly 
selected ART patients.
In the selected group of ART patients, 87.4% received starvudine, lamivudine and nevirapine as 
a first line regimen. The remaining patients in this group received zidovudine, lamivudine and 
nevirapine (6.3%) or efavirenz + emtricitabine + tenofovir disoproxil fumarate (6.3%). Patients 
in the suspected resistance group had received starvudine, lamivudine and nevirapine (76.9%), 
efavirenz + emtricitabine + tenofovir disoproxil fumarate (15.4%) or zidovudine, lamivudine and 
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nevirapine  (7.7%)  as  their  first  line  regimen.  A  second  line  ART  combination  containing 
abacavir,  didanosine  and  ritonavir-boosted  lopinavir  was  given  to  75%  of  patients  in  the 
suspected resistance group. Other patients in this group changed their regimen to zidovudine, 
lamivudine and efevirenz from starvudine,  lamivudine and nevirapine (16.7%) or starvudine, 
lamivudine and nevirapine from zidovudine,  lamivudine and efavirenz (8.3%). The randomly 
selected patients were under treatment for an average of 11.6 months, those in the suspected 
resistance group had been on ART for 19 months at the time of sampling. 
1.29.2 HIV-1 Drug Resistance Mutations
Table  3-13 and  Table  3-14 summarize  resistance  mutations  detected  in  both  groups,  the 
randomly selected patients on ART and the suspected resistance group. In the first group, 2 of 
the  16  (12.5%)  patients  from  whom  sequences  could  be  obtained,  harboured  mutations 
conferring resistance to reverse transcriptase inhibitors. One of these patients carried virus with 
mutations conferring resistance to both NRTIs (M184V) and NNRTIs (G190A), while in the 
other  patient  only  a  NNRTI  mutation  (Y181C)  was  found.  Among  patients  with  suspected 
resistance, 6/17 (35.3%) harboured major mutations to NRTIs and 6/17 (35.3%) major mutations 
to NNRTIs and 7/17 (41.2%) harboured minor RTI mutations.
Out of the 17 individuals with suspected drug resistance, 7 harboured mutated viral strains. In 6 
of  these  7  patients  multiple  mutations  to  both  NRTIs  and  NNRTIs  were  detected.  Two 
individuals (11.8%) in this group also carried minor mutations to protease inhibitors (I54AV, 
I84V and L10F for the first individual and L10I for the second individual).
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1.30 DISCUSSION
Our attempts to genotype viral isolates from randomly selected patients under treatment highlight 
the  limited  sensitivity  of  detection  in  such  samples.  This  argues  for  an  overall  efficacious 
treatment in most KIULARCO patients,  because under optimal ART, VL might  well  remain 
under the detection limit [11]. As a consequence, the number of viral sequences deriving from 
treated  patients  was  very  small  in  our  study.  Nevertheless,  our  findings  provide  a  first  and 
preliminary indication of a rather low frequency of DR-mutations among KIULARCO patients. 
The fact that we were successful in amplifying viral sequences from all cases with suspected 
resistance,  argues against  a technical  problem,  but  indicates  that  the most  probable cause of 
amplification failure was indeed a very low viral load in most of the 137 samples analyzed. The 
16 successful  amplifications  probably  detected  viral  RNA only  in  samples  with  elevated  or 
temporarily raised VL.
However, the 137 randomly selected plasma samples used in our investigation had been stored 
for a considerable period of time prior to our molecular analyses. This might have impaired the 
quality of the viral RNA and thus amplification success. In this case our low sensitivity of RT-
PCR  was  rather  due  to  frequent  power  cuts  and  suboptimal  storage.   Previously  we  have 
analyzed earlier  samples collected from these 137 individuals prior to start of ART. Most of 
these earlier samples yielded a PCR product (Masimba et al. submitted). Considering the low 
efficacy of sequencing viral isolates from patients under ART, the analysis of samples of cohort 
patients not yet under treatment could provide DR-mutation prevalence data much faster. Such 
data would be equally useful for monitoring the spread of DR mutations in the study area.
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Out of the 16 randomly selected individuals on ART, from whom a viral sequence could be 
obtained, two (12.5%) harboured major mutations conferring resistance to reverse transcriptase 
inhibitors. The three mutations detected in this group were Y181C and G190A, both implying 
resistance  to  NNRTIs,  and M184V, conferring  resistance  to  NRTIs.  Patients  were  receiving 
combination therapy containing starvudine lamivudine and nevirapine for a mean duration of 
almost 1 year.  The M184V mutation has been reported to be selected in patients receiving a 
lamivudine containing regimen [12] [13]. 
Several studies conducted in different parts of Africa have reported varying prevalence rates of 
DR mutations for patients receiving ART. Dagnra et al. (2011) reported a prevalence of 24.5% 
for patients receiving the same combination of ART as used in our study for 12 months in Lome, 
Togo [14]. This higher prevalence was explained by the fact that half of the patients in the Togo 
study had interrupted their treatment for >1 month. Among 16 patients, only one was reported to 
be non-adherent. Because no adherence problems were evident in case report forms of our 16 
ART recipients with PCR amplified viral sequences, the discrepancy in adherence between our 
patients and those in Togo could explain the observed difference in DR mutation prevalence. 
Several other factors, such as suboptimal drug levels due to differences in host drug metabolism, 
presence of other  diseases interfering with drug absorption,  drug toxicity,  use of low potent 
drugs, non-adherence and long duration  of ART are known to contribute to development of 
resistance in HIV-1 treated patients [7] [8]. None of these factors have been investigated so far in 
KIULARCO patients. In general, adherence in the studied subset of KIULARCO patients was 
good. Adherence information was extracted from medical reports, but this can not rule out the 
possibility  of  missed  doses.  In  a  study conducted  in  2003 in  Kampala,  Uganda,  a  mutation 
prevalence  of  19% was  observed  for  major  NNRTIs  mutations  and 16.8% for  major  NRTI 
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mutations in patients receiving a nevirapine-based or efavirenz-based combination therapy (74% 
and 26% of patients, respectively) for >9.5 months. In the Ugandan study, 23% of patients had 
reported  treatment  interruption  for  >4  days  and  these  treatment  interruptions  were  strongly 
associated  with  virological  failure  [15].  In  Haydom,  rural  Tanzania,  where  ART  had  been 
provided since 2003, major DR mutations were detected in samples from 2007 and 2008 at a 
prevalence of 3.9% for patients who had been on ART for 1 year [10]. As reasons for the good 
ART response to treatment in this study the following concomitant factors were given: adherence 
counselling,  presence  of  home-based  carers,  regular  peer-support  meetings,  and  continuous 
uninterrupted drug supply. 
The 12.5% prevalence of major mutations detected in KIULARCO patients under ART is three 
times higher than results from the Hydom study, which was conducted also in a rural area in 
Northen-East,  Tanzania  [10].  It  is  also  higher  than  the  results  obtained  from  Kagera  and 
Kilimanjaro  studies  [7].  The  observed  relatively  high  prevalence  of  DR  mutations  among 
KIULARCO treatment experienced patients supports our hypothesis on increased numbers of 
mutations in rural settings. The possible explanation for this still moderately high level of genetic 
resistance could be due to drug stock outs or drug adherence problems in some patients. These 
findings emphasize that it is only possible to achieve high ART efficiency in a rural setting when 
ART programs are well organized and coordinated to ensure optimal ART delivery and usage, 
and that this programmes should be carefully monitored.
Among the patients with suspected DR, 6/17 patients (35.3%) harboured major DR mutations 
affecting both, NRTIs and NNRTIs. These patients had started ART at a mean CD4 count of 188 
cells/ml and had been on an either  nevirapine-based combination (84.6%) or efavirenz-based 
combination (15.4%) for a mean period of 19 months. The average CD4 counts at the time of 
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first  ART change was 76 cells/µl.  Such a low CD4 count  was one of two criteria  used for  
defining a suspected case of resistance. The second clinical criterion was based on WHO clinical 
staging. In this group of suspected DR cases, the mean duration of ART was 19 months, which 
exceeded that in our randomly selected ART patients by 7 months. Mutations associated with 
DR have been shown to increase with the time elapsed since ART initiation [10]. It possible that 
the longer lasting ART in suspected DR cases could have contributed to the emergence of the 
observed mutations, but primary resistance in these patients cannot be ruled out. 
The  most  common  mutations  in  cases  of  suspected  DR were  Y181C,  G190A,  and  K103N 
(NNRTIs)  and  M41L,  M184V,  D67N  and  T215F/Y  (NRTIs).  These  mutations  were  also 
reported from patients failing their first ART regimen in other studies [16] [17] [18] [19]. Some 
of the minor RT mutations observed in this group have some clinical impact when occurring in 
association with major RT mutations. For example, E44D when occurs with M41L, as seen in 
patient  (ID 7150047,  increases  resistance  to  NRTI,  in  particular  to  lamividune  [20].  F116Y 
belongs to the Q151M cluster that is associated with resistance to multiple NRTIs. Both F116Y 
and Q151 were observed in patient ID 7121093. In 2002, Deval and coworkers found that this 
haplotype  exerts  its  effects  through  substrate  discrimination  at  the  level  of  nucleotide 
incorporation  [21].  All  patients  with  suspected  DR,  who harboured  major  mutations  in  RT, 
carried at least one minor mutation. It is likely that this combination of mutations contributed to 
the reduced ART efficacy in these patients. 
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The presence of only few minor mutations PR and the absence of major mutations in PR in our  
study are consistent with the rare use of protease inhibitors in KIULARCO [3]. PR inhibitors are 
used  only  as  second  line  drugs  in  Tanzanian  and  Sub-Saharan  Africa  [2]  [6].  Similar  low 
frequency of minor PR mutations or absence of major PR mutations have been reported from 
other sites with no or very restricted use of PR inhibitors [22].
1.31 CONCLUSION
Our pilot data has shown for KIULARCO patients under ART that a prevalence of DR mutations 
is lower than in other parts of Africa, but 3-fold higher than reports from another rural site in  
Tanzania.  This  suggests  that  the  KIULARCO  ART  program  has  some  limitations  in  its 
effectiveness. In 17 patients with suspected drug resistance, major DR mutations were observed 
at a prevalence of 35%. Yet, the majority of these 17 treatment failures seemed to be due to 
causes other than the genetic background of the virus, e.g. compliance with treatment, and hence 
further  studies  are  needed  to  investigate  these  factors.  Continuous  monitoring  should  be 
instituted to further improve the outcome of the ART programme in this cohort.
1.32 ACKNOWLEDGEMENTS
We would like to thank all staff and management of the Chronic Disease Clinic of Ifakara, St.  
Francis  Referral  Hospital, and  Cristel  Wadia  at  the  Institute  for  Medical  Microbiology, 
University of Basel for their valuable contribution in this work. This work was supported by the 
Swiss National Science Foundation grant no. IZ70Z0-131378.
81
HIV-1 drug resistance mutations in patients under treatment from a cohort in rural Tanzania
1.32.1 REFERENCES
1. National  AIDS  Control  Programme,  HIV_AIDS_STI  Surveillance  Report  Number  21. 
Issued July 2009.pdf. 
2. National  AIDS  Control  Programme,  National_Guidelines_for_the 
Management_of_HIV_and_AIDS-February 2009.pdf. 
3. Mossdorf E, Stoeckle M, Mwaigomole E, et al. Improved antiretroviral treatment outcome in 
a rural African setting is associated with cART initiation at higher CD4 cell counts and better 
general health condition. BMC Infectious Diseases 2011; 11:98. 
4. Bannister WP, Cozzi-Lepri A, Kjær J, et al. Estimating prevalence of accumulated HIV-1 
drug resistance in a cohort of patients  on antiretroviral  therapy.  Journal of Antimicrobial 
Chemotherapy 2011; 66:901 -911. 
5. Napravnik  S,  Keys  JR,  Quinlivan  EB,  Wohl  DA,  Mikeal  OV,  Eron  JJ.  Triple-class 
antiretroviral  drug  resistance:  risk  and  predictors  among  HIV-1-infected  patients.  AIDS 
2007; 21:825-834. 
6. Harries A, Nyangulu D, Hargreaves N, Kaluwa O, Salaniponi F. Preventing antiretroviral 
anarchy in sub-Saharan Africa. The Lancet 2001; 358:410-414. 
7. Nyombi  B,  Holm-Hansen  C,  Kristiansen  K,  Bjune  G,  Muller  F.  Prevalence  of  reverse 
transcriptase  and protease mutations  associated  with antiretroviral  drug resistance among 
drug-naive HIV-1 infected pregnant women in Kagera and Kilimanjaro regions, Tanzania. 
AIDS Research and Therapy 2008; 5:13. 
8. Ramadhani HO, Thielman NM, Landman KZ, et al.  Predictors of Incomplete Adherence, 
Virologic  Failure,  and  Antiviral  Drug  Resistance  among  HIV-Infected  Adults  Receiving 
Antiretroviral Therapy in Tanzania. Clinical Infectious Diseases 2007; 45:1492 -1498. 
9. Johannessen A, Naman E, Ngowi B. Predictors of mortality in HIV-infected patients starting 
antiretroviral  therapy in a  rural  hospital  in  Tanzania.  BMC Infectious  Diseases  2008;  8. 
Available at: http://www.biomedcentral.com/1471-2334/8/52.
10. Johannessen A, Naman E, Kivuyo S. Virological efficacy and emergence of drug resistance 
in adults on antiretroviral  treatment in rural Tanzania.  BMC Infectious Diseases  2009; 9. 
Available at: http://www.biomedcentral.com/1471-2334/9/108.
11. Hermankova M, Ray SC, Ruff C, et al.  HIV-1 Drug Resistance Profiles in Children and 
Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy. JAMA: The 
Journal of the American Medical Association 2001; 286:196 -207. 
12. Diallo K, Götte M, Wainberg MA. Molecular Impact of the M184V Mutation in Human 
Immunodeficiency  Virus  Type  1  Reverse  Transcriptase.  Antimicrobial  Agents  and 
Chemotherapy 2003; 47:3377 -3383. 
82
HIV-1 drug resistance mutations in patients under treatment from a cohort in rural Tanzania
13. Buckton  AJ,  Prabhu  D,  Motamed  C,  et  al.  Increased  detection  of  the  HIV‐1  reverse 
transcriptase  M184V  mutation  using  mutation‐specific  minority  assays  in  a  UK 
surveillance  study  suggests  evidence  of  unrecognized  transmitted  drug  resistance.  HIV 
Medicine 2011; 12:250-254. 
14. Dagnra AY, Vidal N, Mensah A, et al.  High prevalence of HIV-1 drug resistance among 
patients  on first-line  antiretroviral  treatment  in  Lomé,  Togo.  Journal  of  the  International 
AIDS Society 2011; 14:30. 
15. Spacek LA, Shihab HM, Kamya MR, et  al.  Response to Antiretroviral  Therapy in HIV-
Infected Patients Attending a Public, Urban Clinic in Kampala, Uganda. Clinical Infectious 
Diseases 2006; 42:252 -259. 
16. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 Drug Resistance after Failure of a 
First  Highly  Active  Antiretroviral  Therapy  Regimen  in  KwaZulu  Natal,  South  Africa. 
Clinical Infectious Diseases 2008; 46:1589 -1597. 
17. Muwonga J, Edidi S, Butel C, et al. Resistance to Antiretroviral Drugs in Treated and Drug-
Naive Patients in the Democratic Republic of Congo. JAIDS Journal of Acquired Immune 
Deficiency Syndromes 2011; 57:S27-S33. 
18. Sigaloff KCE, Ramatsebe T, Viana R, Wit TFR de, Wallis CL, Stevens WS. Accumulation 
of HIV Drug Resistance Mutations in Patients Failing First-Line Antiretroviral Treatment in 
South Africa. AIDS Research and Human Retroviruses 2011; :110805091412002. 
19. El-Khatib Z, Ekstrom AM, Ledwaba J,  et  al.  Viremia and drug resistance among HIV-1 
patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 
2010; 24:1679-1687. 
20. Girouard M, Diallo K, Marchand B, McCormick S, Götte M. Mutations E44D and V118I in 
the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to 
AZT and 3TC. Journal of Biological Chemistry 2003; 278:34403 -34410. 
21. Deval J, Selmi B, Boretto J, et al. The molecular mechanism of multidrug resistance by the 
Q151M human  immunodeficiency  virus  type  1  reverse  transcriptase  and  its  suppression 
using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 2002; 277:42097-42104. 
22. Richard N, Juntilla M, Abraha A, et al. High prevalence of antiretroviral resistance in treated 
Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res. 
Hum. Retroviruses 2004; 20:355-364. 
Table 3-11: Baseline characteristics of studied subset of KIULARCO patients 
Variable Value  %
WHO Stage (n = 116)
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1 39 33.6
2 22 19.0
3 35 30.2
4 20 17.2
Sex (n = 117)
Females 80 68.4
Males 37 31.6
HIV-1 Subtype (n = 119)
A 31 28.0
C 52 37.3
CRF01_AE 11 10.7
D 28 24.0
CD4 counts (cells/μl) (n = 119)
Mean 278 na
Viral Load (copies/ml) (n = 90)
Mean 124 904 na
Age (Years) (n = 116)
Mean 37 na
First ART Regimen (n = 97)
1a 67 69.1
1b 1 1.0
1c 24 24.7
1d 2 2.1
1e 3 3.1
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1a,  starvudine  +  lamivudine  +  nevirapine;  1b,  zidovudine  +  lamivudine  +  nevirapine;  1c, 
zidovudine + lamivudine + efavirenz,  Adults  and Paediatrics;  1d, starvudine + lamivudine + 
efavirenz; 1e, efavirenz + emtricitabine + tenofovir disoproxil fumarate. na, not applicable. 
Table 3-12: Characteristics of study participants with detectable viral RNA
Characteristic Patients on ART 
(n= 16)
Suspected 
Resistance Cases 
(n= 17)
Age (years)
Mean 36 31
Sex (percent)
Female 50 64.3
Male 50 35.7
CD4 Counts at baseline(Cells/µl)
Mean 247 ± 187 188 ± 78
CD4 Counts at First ART change (Cells/µl)
Mean na 76 ± 60
Viral load (Copies/mL)
Mean 171 443 ± 
297 083
317 955 ±
636 925
WHO Stage (percent)
WHO 1 25 41.7
WHO 2 0 25.0
WHO 3 75 8.3
WHO 4 0 25.0
Duration on 1st ART 
(Months)
Mean 11.6 19
1st Regimen (percent)
1a(30) 87.5 76.9
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1b 6.3 7.7
1c 0 15.4
1e 6.3 0
Second ART (percent) (n = 1) (n = 12)
1c 0 16.7
1a(30) 0 8.3
2a 0 75.0
ART, antiretroviral therapy; NRTIs, Nucleoside reverse-transcripatse inhibitors; NNRTIs, Non-
nucleoside  reverse-transcripatse  inhibitors;  PIs,  Protease inhibitors;  1a(30),  starvudine  (30)  + 
lamivudine  +  nevirapine,  adults;  1b,  zidovudine  +  lamivudine  +  nevirapine,  adults  and 
paediatrics; 1c, zidovudine + lamivudine + efavirenz, adults and paediatrics ; 1e, efavirenz + 
emtricitabine + tenofovir disoproxil fumarate; na, not applicable (not done).
86
HIV-1 drug resistance mutations in patients under treatment from a cohort in rural Tanzania
Table 3-13: Drug resistance mutations in randomly selected patients on ART 
and in suspected resistance cases
   Patient ID HIV-1
Subtype 
Sex Age Mutation Drug Class Regimen 
Used
NRTIs NNRTIs PIs
Randomly 
selected 
patients under 
ART
5510425 C F 38 - K101Na - 1a (30) 
5510599 C F 52 - Y181C 
G190Ra
- 1a (30)
5510817 C M 55 - A98Ga - 1a(30)
5510423 C M 35 - K103Ra - 1a(30)
5510255 A F 13 M184V G190A 
E138Qa
- 1b
5510270 C F 8 M41Ia
K103Ra
- - 1a(30)
Suspected 
resistance
cases
7150047 CRFAE_
01
M 60 M41L 
E44Da
M184V 
L210Sa
T215Y
G190A 
A98Ga 
K101Ea 
V179Ta
I54AV
a
I84Va
L10Fa
1a(30)
5510582 C F 12 - V106Na - 1b
5510946 A M 42 M41L 
D67N
V75M 
L210W
T215F
L100ILV
aK103Na 
V108ILV
a E138Ra
V179Ta
G190S
H221Ya
L10Ia 1c
5510628 C M 32 M41L 
D67N 
Y181YC - 1c
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K70R 
V75M 
M184V 
T215F 
K219E
G190S
5510255 CRF01_
AE
F 16 M184V G190A
K101Ea 
E138Qa
- 1a(30)
5511110 C F 24 D67N 
D67Ta 
Q151M 
M184I 
K219Q
V90Ia 
K101aQ 
K103N 
Y181C
G190A
- 1a(30)
7121093 C F 37 M184V 
F116Y 
Q151M 
T215Y
K103N - 1a(30)
ART, Antiretroviral therapy; NRTIs, Nucleoside reverse-transcripatse inhibitors; NNRTIs, Non-
nucleoside reverse-transcripatse inhibitors;  PIs,  Protease inhibitors;  1a(30), Starvudine (30) + 
Lamivudine  +  Nevirapine,  Adults;  1b,  Zidovudine  +  Lamivudine  +  Nevirapine,  Adults  and 
Paediatrics;  1c,  Zidovudine  +  Lamivudine  +  Efavirenz,  Adults  and  Paediatrics  ;  Atripla, 
Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate. 
aMinor HIV-1 drug resistance mutations 
Table 3-14: Frequencies of DR mutations in randomly selected patients on ART 
and in suspected drug resistance patients
Type of Mutation
Randomly selected patients 
on ART (n = 16)
Suspected resistance cases
(n = 17)
Frequency Percentage Frequency Percentage
Major NRTI Mutations 
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M41L 0 0 3 17.6
D67N 0 0 3 17.6
K70R 0 0 1 5.9
V75M 0 0 2 11.8
Q151M 0 0 2 11.8
M184V 1 6.3 4 23.5
L210W 0 0 1 5.9
T215Y 0 0 2 11.8
T215F 0 0 2 11.8
K219E 0 0 1 5.9
K219Q 0 0 1 5.9
Individuals with 
major NRTI 
mutations
1 6.3 6 35.3
Major NNRTI Mutations
L100I 0 0 1 5.9
K103N 0 0 3 17.6
Y181C 1 6.3 2 11.8
G190A 1 6.3 3 17.6
G190S 0 0 2 11.8
Individuals with 
major NNRTI 
mutations
2 12.5 6 35.3
Individuals with 
major RTI mutations
2 12.5 6 35.3
Minor RTI mutations
M41I 1 6.3 0 0
E44D 0 0 1 5.9
D67T 0 0 1 5.9
V90I 0 0 1 5.9
A98G 1 6.3 1 5.9
L100V 0 0 1 5.9
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K101E 0 0 2 11.8
K101N 1 6.3 0 0
K101Q 0 0 1 5.9
K103R 1 6.3 0 0
V106N 0 0 1 5.9
V108IL 0 0 1 5.9
F116Y 0 0 1 5.9
E138R 0 0 1 5.9
E138Q 1 6.3 1 5.9
V179T 0 0 2 11.8
G190R 1 6.3 0 0
L210S 0 0 1 5.9
L221Y 0 0 1 5.9
L234S 0 0 1 5.9
Individuals with 
Minor RTI 
mutations
6 37.5 7 41.2
Minor PI Mutations
L10I 0 0 1 5.9
L10F 0 0 1 5.9
I54AV 0 0 1 5.9
I84V 0 0 1 5.9
Individuals with 
minor PRI mutations
0 0 2 11.8
ART, antiretroviral therapy; DR-mutations, drug resistance mutations; NRTI, nucleoside reverse-
transcriptase  inhibitor;  NNRTI,  non-nucleoside  reverse-transcriptase  inhibitors;  PI,  protease 
inhibitor
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1.33 ABSTRACT
1.33.1 BACKGROUND
The success of antiretroviral therapy (ART) to HIV-1 is compromised by development of drug 
resistance (DR) due to mutations in viral genes, the product of which is targeted by ART drugs. 
For ART deployed in resource poor settings, the viral reverse transcriptase (RT) is the main drug 
target, and to a lesser extend also protease (PR). Monitoring of these DR mutations in both drug 
naïve and drug experienced patients can contribute to optimization of ART at individual and 
population level. In Tanzania molecular analyses of DR are limited in their availability owing to 
high costs. Therefore, a simple, cheap and robust tool for DR genotyping was developed based 
on microarray technology.  Detection  of  single nucleotide  polymorphism (SNP) was targeted 
specifically at local strains prevailing in the HIV-1 cohort in Ifakara, rural Tanzania, and was 
restricted to those 25 DR mutations most relevant for the locally available ART regimen. 
1.33.2 METHODS
A 645 bp fragment of the RT gene was reverse transcribed and amplified by PCR. Primers for 
mini-sequencing were designed based on alignments of local HIV-1 variants.  Tagged primers, 
positioned  directly  adjacent  to  the  SNP,  were  extended  by  1  fluorochrome-labeled 
dideoxynuclotide triphosphate (ddNTPs), whereby this nucleotide,  enzymatically incorporated 
according to base pairing rules, indicated the SNP allele of the sample tested. Extension products 
were hybridized to anti-tags spotted on microarray slides. Images on the slide were analyzed 
with  a  laser  scanner  and  Genepix  software.  Genotype  calling  was  performed  with  in-house 
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developed software. This HIV-1 typing tool was validated with 102 HIV-1 directly sequenced 
samples deriving from the Tanzanian target population.
1.33.3 RESULTS AND CONCLUSION
Microarray derived genotypes were concordant with the corresponding sequence-based SNP in 
92.7%  of  the  2550  compared.  Once  the  locally  adapted  microarray  had  been  established, 
genotyping was easy to perform and completed within 4 hours. Major problems were missing 
data,  as  some  SNPs  could  not  be  detected  in  some  samples,  possibly  due  to  excessive 
mismatches  between  PCR  product  and  extension  primer.  Nine-teen  SNPs  were  genotyped 
reliably, while performance was suboptimal for six SNPs.  Due to missing data this SNP array 
should be considered preferentially for population studies on prevalence of SNPs rather than for 
individual diagnostics and represents a fast and cheap alternative to sequencing.
1.34 INTRODUCTION
Development of HIV-1 drug resistance has been one of the major obstacles in the success of 
Antiretroviral Therapy (ART) to HIV-1 patients [1]. One of the major factors which accounts for 
the  development  of  resistance  to  these  drugs  is  the  emergence  of  mutations  in  the  reverse 
transcriptase (RT) gene which is among the HIV-1 drug targets (2).
A number of phenotypic and genotypic assays have been used to detect HIV-1 drug resistance 
(DR) mutations (3). Phenotypic assays measure directly the extent to which an antiretroviral drug 
inhibits  HIV-1 virus  replication  in  vitro,  and  is  performed  by measuring  an  increase  in  the 
inhibitory concentration (IC) that  is required to inhibit  in-vitro growth by 50 percent  (IC50) 
compared with virus replication in the absence of drug. Results are reported as a fold-change in 
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drug  susceptibility  of  the  patient  sample  compared  with  a  laboratory  reference  strain  (4). 
Phenotypic testing reflects the net effect of HIV-1 mutations on susceptibility to each tested drug 
and is more useful in patients with complex mutation patterns (5). Genotypic assays identify DR-
associated  mutations  in viral  RNA isolated  from HIV-infected  individuals.  In comparison to 
phenotypic assays, genotypic testing is considered to have the advantages of rapid turn-around 
time of about 1-2 weeks, lower cost, and enhanced detection of resistance-associated mutations 
in mixed virus populations (5).
In developed countries, both genotypic and phenotypic assays are used for monitoring HIV-1 
patients  at  the  beginning  of  ART,  and  in  case  of  suspected  drug  resistance.  Due  to  their 
prohibitive costs, these assays are not available in developing countries like Tanzania,  where the 
number of patients under ART has increased massively since the start of the National programme 
(NACP) in  2004 (6). In view of the rapidly increasing need for molecular monitoring of the 
prevalence and spread of DR also in resource-poor settings,  an additional  molecular  tool for 
robust and cheap DR genotyping is warranted. While nucleotide sequencing certainly remains 
the gold standard for molecular detection of DR-SNPs, surveillance of population samples and 
molecular epidemiological research project could greatly benefit from a highly parallel and fast 
tool to determine only a small number of DR-SNPs that are most essential for a specific location 
and available drugs. We therefore investigated the option to genotype multiple SNPs using a 
microarray platform. 
A microarray platform had been developed previously in our laboratory for detection of SNPs in 
drug resistance marker genes of malaria parasites (7). For this application the mini-sequencing 
principle provided highly specific base calling and parallel genotyping of many SNPs at a time 
(8). We intended to adopt this platform for genotyping local HIV-1 variant in Ifakara. For proof-
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of-concept this development of an HIV-1 microarray was restricted to genotyping only mutations 
associated with resistance to reverse transcriptase inhibitors (RTI), in particular those that were 
used in the Ifakara HIV-1 cohort, i.e. starvudine, lamivudine, zidovudine, abacavir, didanosine, 
nevirapine and efavirenz.
Due to the high error rate of HIV-1 reverse transcriptase,  a very extensive polymorphism is 
observed among the HIV-1 strains.  Therefore primers  needed to be designed based on local 
subtypes  and strains occurring in the study area.  Our intention was to provide an affordable 
option for monitoring HIV-1 drug resistance in Tanzania by genotyping on microarray, which 
permits highly multiplexed SNP analysis in a single run and also requires less hand-on-time and 
resources (7). 
1.35 MATERIALS AND METHODS
Viral  RNA  was  extracted  and  reverse  transcribed  from  140  μl  plasma  collected  from  102 
Tanzanian HIV-1 patients attending the Chronic Disease Centre of Ifakara (CDCI) at St. Francis 
Referral  Hospital  (SFRH).  All  procedures  have  been  described  previously  (Masimba  et  al. 
submitted manuscript). A fragment of 645bp spanning positions 23 – 236 in the RT gene was 
amplified by nested PCR as described.  
1.35.1 Design of Extension Primers, Tags and Anti-Tags
Extension primers were designed for 25 prioritized DR-SNPs in the RT gene. Per SNP one or 
more extension primers were designed using a Clustalw1 alignment of 126 sequences from HIV-
1  samples  of  patients  from  the  KIULARCO  cohort  in  Ifakara,  Tanzania.  These  sequences 
derived from a molecular epidemiological study presented elsewhere (Masimba et al. submitted 
96
Development for a Microarray for Genotyping HIV-1 Drug Resistance Mutations in the Reverse 
Transcriptase Gene
manuscript).  Extension  primers  were  designed  in  either  the  forward  or  reverse  direction  to 
maximize  sequence  conservation  between  the  designed  primer  and  the  variety  of  template 
sequences. Single base extension (SBE) software (9) was used to design a set of 100 tags and 
anti-tags under the following parameters: length 17-25 bp, melting temperature (Tm) 53-62°C, 
homodimer temperature 400C. One individual tag was added to the 5` end of a single extension 
primer, whereby the SBE program was used to select the optimal tag/extension primer pairs by 
assessing  the  Tm  and  the  potential  for  hair-pin  formation,  homodimer  and  heterodimer 
formation. For spotting on microarrays 55 anti-tags, i.e. reverse complement of the tags selected 
for the extension primers, were synthesized via a C7 aminolinker for covalent coupling to the 
aldehydeglass slide. Oligonucleotides used as extension primers, anti-tags, as well as Cy5- and 
Cy3-prelabeled  oligonucleotides  used  as  spotting  controls  and  one  additional  Cy5-labelled 
hybrization  control  were  all  purchased  from  Eurofins  MWG/Operon  GmbH  (Ebersberg, 
München,  German).   Labeled  ddNTPs  were  purchased  from Perkin  Elmer,  Schwerzenbach, 
Switzerland.
1.35.2 Array design and production
55 anti-tags plus 2 Cy3- and Cy5-prelabeled spotting controls  were spotted at  the Center of 
Integrative Genomics, University of Lausanne, Switzerland, on Arrayit aldehyde-coated slides 
with  a  12  well  mask  (Supermask  12  Super  Aldehyde  Slides  purchased  from  Anopoli, 
Eichgraben,  Austria).  Oligonucleotides  were  dissolved as  a  10x stock  (500µM) in  180 mM 
phosphate buffer pH 8.0 and spotted after dilution in spotting buffer (3xSSC buffer with 1.5 M 
betaine) at a concentration of 50 μM (labeled spotting controls at a concentration of 0.5 μM). 
The array design featured 14X14 spots with a spot-to-spot distance of 250 µm and was printed in 
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triplicate  per  masked  well.  After  printing,  slides  were  kept  on  a  chamber  at  50%  relative 
humidity and baked the next day at 80°C for 90 min.
Prior to hybridization slides were pre-treated by an incubation at 80°C for 90 min, followed by 
washing  steps,  2x2  min  in  0.2%  SDS  and   3x2  min  in  distilled  water  and  was  dried  by 
centrifugation at 800 rpm for 5 min, reduced in 50mM triethanolamine titrated with boric acid to 
pH 8.0 at 500C for 30 minutes, washed three times with 0.2% SDS for 1 minute, washed twice in 
distilled water for 1 minute and finally dried by centrifugation for 5 minutes at 800 rpm. Slides 
were then kept at room temperature in a dry, clean and dark place until used in hybridization 
experiments.
1.35.3 Primer Extension and hybridization
Prior to  the primer extension reaction,  nested RT-PCR products were subjected to a Shrimp 
Alkaline Phosphatase (SAP) digest (Amersham Biosciences, Freiburg, Germany) to eliminate all 
non incorporated nucleotides. This reaction was carried out as previously described (1). Primer 
extension with Cyanine-3 and Cyanine-5 labeled dideoxynucleotide Triphosphates (Cy3-ddNTPs 
and Cy5-ddNTPs from Perkin Elmer, Schwerzenbach, Switzerland) was carried out as described 
previously  (7).  Because  the  scanner  used  supported  only  dual  fluorescence  measures,  two 
extension  reactions  were  performed  with  different  permutations  of  Cy3  and  Cy5  labelled 
ddNTPs.  Table 4-15 shows the composition of both reaction mixes and indicates the required 
reaction  mix  for  each  extension  primer.    These  two combinations  of  differentially  labeled 
ddNTP were sufficient  to  differentiate  all  wild-type  from mutant  alleles.  Extension products 
from  both  reactions  were  combined  before  denaturation  and  hybridization  performed  as 
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described previously (7) with one modification in that hybridization was performed at 550C for 
two hours.
1.35.4 Washing 
After  hybridization,  the  slide  washed  at  room  temperature  (200C)  in  3  consecutive  buffers 
(temperature of the washing buffer was set at around 250C). One wash round consisted of 2X 
SSC + 0.2% SDS for 3 minutes,  followed by 2X SSC for 2 min and finally 2X SSC + 2% 
Ethanol  for  1  min.  The  number  of  rounds  depended  on  the  background  fluorescence  and 
fluorescence intensity of spots. To adjust washing conditions to the background intensity, a slide 
was quickly dried with compressed air after each round and then pre-scanned. This was followed 
by  additional  rounds  until  the  background  fluorescence  was  satisfactorily  removed  without 
compromising signal intensity yet. Usually three rounds were necessary. 
1.35.5 Image and Genotype Scoring
After drying a slide was scanned in a GenePix® microarray scanner 4100A (Axon Instruments, 
Genepix, USA) and images were stored as Tagged Image File Format (TIFF) file. Images were 
interpreted by running the Genepix software in combination  with a file  containing  the array 
layout. All spots with pre-labeled tags or anti-tags gave strong signals at their defined locations 
and could thus be used to position the array. The data retrieved was stored in a GenePix Result  
(GPR)  file  which  was  transferred  to  an  in  house  generated  receiver  operating  characteristic 
(ROC) Classifier  program for SNP calling.  This program evaluated  and scored the triplicate 
hybridization signals for each SNP into wildtype or mutant based on threshold values from a set 
of positive (triplicate spotting and hybridization controls and negative (unused anti-tags) controls 
present on each slide. 
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1.35.6 Cloned HIV plasmids   
Cloned fragments of the HIV-1 genome were used for microarray validation. These fragments, 
derived from anonymized  Swiss  HIV-1 Cohort  samples  and cloned in  puc18 plasmids  were 
made available from the Institute for Medical Microbiology, University of Basel (10). Individual 
bacterial colonies were picked and plasmid DNA was extracted using QIAprep Miniprep Spin 
colums (Qiagen, Germany) according to the manufacturer’s instructions. Therefore, each of these 
cloned fragments represented an individual HIV-1 RT gene, thus suitable for test validation and 
assessing background hybridization.  Plasmid inserts were of HIV-1 subtype A, AE/A or C. 
1.36 RESULTS
1.36.1 Design of extension primers, tags and anti-tags
For 25 SNPs in the RT gene a total of 51 extension primers (1 to 8 extension primers per SNP)  
were designed to compensate genetic diversity in the targeted sequence. Extension primers, tags 
and anti-tags are listed in Table 4-16.   Prior to hybridization experiments, all extension primers 
were tested by individual PCRs involving one of the extension primers plus either the forward or 
reverse primers normally used in nPCR. As templates 4 cloned RT gene fragments (subtypes A, 
AE2 and C) were used as well  as 102 RT-PCR products from Tanzanian HIV patients.  All 
extension primers yielded DNA fragments of the expected size, indicating a sufficient degree of 
sequence conservation between these primers and the different templates tested (Figure 4-13).  
1.36.2 Array design and spotting 
SBE software was used to select 55 oligonuclotide anti-tags and 2 spotting 
controls, the latter being produced with Cy3 or Cy5 fluorescent label at their 3’ 
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end. One anti-tag was reserved for a hybridization control, for which the Cy5 pre-
labeled tag was added to the extended primers prior to hybridization. Unused tags 
and printed buffer spots were used as negative controls. The array printed on 
Arrayit slides consisted of triplicates of the 55 anti-tags and controls in a 14x14 
spot lay out (A      B), thus generating 3 data points for each position per sample. 
The separation of each slide by a mask permitted to test in 12 patient samples. 
The Cy5-labelled spotting control was found to decay fast during storage of 
slides, in contrast to the Cy3-control. Therefore the hybridization control also 
carrying a Cy5 label was used to control hybridization success and to support 
correct positioning of the array for which fixed and strong signals were required. 
Quantitative results obtained from all pre-labeled controls suggested a good 
reproducibility of the hybridization on microarray. 
1.36.3 Optimization of washing
Despite  systemic  tag/anti-tag  design,  establishing  of  optimal  wash conditions  for  hybridized 
slides was a challenge in generating optimal signal intensities for all  spots of an array.   The 
number of wash steps depended on the background fluorescence and the spot intensity on each 
particular slide and had to be adapted after a pre-scan after each washing round. Most slides were 
washed three times, with each round consisting of 2X SSC + 0.2% SDS for 3 minutes, followed 
by 2X SSC for 2 min and finally 2X SSC + 2% Ethanol for 1 min. Minor differences in slide  
pretreatment conditions and duration of storage could have contributed to these differences. 
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1.36.4 Comparison of microarray-based SNP typing and direct sequencing using cloned 
RT fragments and 102 field samples from Tanzania
In  contrast  to  PCR  fragments  from  field  samples,  which  likely  represent  populations  of 
sequences, cloned HIV-1 genome fragments harbor a single sequence and were therefore ideal 
for validating the specificity of hybridization on microarray and for determining individual anti-
tags that give rise to hybridization background. Four cloned fragments,  generated previously 
from Swiss HIV-1 cohort samples, were used, which represented sequences of subtypes C, AE2 
and  A2.  For  these  cloned  RT  genes,  the  agreement  between  microarray  results  and  direct 
sequencing varied for the different cloned fragments. With 2 plasmids containing C1 and A2 
subtype  sequences  (0720235-C1  and  070510-A2),  perfect  agreement  between  sequence  and 
microarray genotype was obtained, whereas only 88% agreement was reached for a plasmid with 
a AE2 subtype insert (6017225-AE2) and 72% for a subtype C1 insert (072073-C1). Because 
these  plasmid  inserts  derived  from patients  of  a  Swiss  HIV cohort,  they  likely  represented 
variants with substantial  sequence deviation from our extension primer sequences, which had 
been optimized for Tanzanian subtypes. Overall the concordance between both typing methods 
was 90%, the data for each SNP tested is shown in Table 4-17.
Next our HIV-1 SNP array was validated by typing 102 field samples from HIV-1 patients from 
Ifakara, Tanzania. The agreement between microarray and direct sequencing was 92.7% (Table
4-17). Extension primers of 5 SNPs had concordance of 100%. 14 SNPs had a concordance of 
more  than  90% and  only  one  SNP  had  concordance  of  less  than  70% compared  to  direct 
sequencing. The SNPs with 100% agreement were: M41L1, L74V, V75I, T215FY and K219E. 
The SNPs with between 90% - 99% agreement were: M41L, D67E, K70R, T215FY1, T215FY2 
and L74I (99%), K219Q (98%), L100I, Y181C and M184V (96.1%), M184I (95.1%), G190A 
102
Development for a Microarray for Genotyping HIV-1 Drug Resistance Mutations in the Reverse 
Transcriptase Gene
and K103N (93.1%). The SNPs with <90% agreement were: D67N (87.3%), Y188L1 (86.3%), 
K219N (78.4%),  Y188l2  (71.6%) and L210W (62.7%).  The L210W SNP performed  poorly 
compared  to  all  other  SNPs.  The  sequence  alignment  of  all  102  Tanzanian  samples  tested 
sequences revealed in samples which failed to produce a signal a number of mismatches with the 
designed extension primer. Thus, the extension primer for SNP L210W was located in a region 
of considerable polymorphism and we failed to design a primer which would harbour less than 
three mismatches  with any of the sequences.  To compensate  the polymorphism around SNP 
L210W, a total of 8 extension primers were designed for this SNP alone, but still only 60% of 
samples produced a signal by all these primers together. Primer mismatches seemed to be the 
main reason for missing data and the wrong signals. Another SNP, Y181C, initially also suffered 
from missing data,  but  after  re-designing a  set  of  5  extension  primers  for this  SNP,  correct 
signals were recovered and in  96% of samples. 
1.37 DISCUSSION
The microarray-based SNP typing approach, originally developed and in use in our laboratory 
for  several  years  for  genotypng  DR resistance  marker  of  the  malaria  parasite  Plasmodium 
falciparum,  (7)  was  applied  for  genotyping  DR-SNPs  in  the  RT  gene  of  HIV-1.  The  high 
mutation  rate  and  genetic  diversity  questioned  a  solely  hybridization-based  approach.  Our 
approach  tried  to  overcome  this  challenge  by  (i)  performing  allelic  discrimination  in  an 
unequivocal enzymatic reaction by applying the mini-sequencing principle, and (ii) adapting the 
extension  primers  to  the  locally  prevailing  viral  strains,  i.e.  producing  a  genotyping  tool 
dedicated for our specific population and country. In our experiments hybridization on micrarray 
was limited to perfectly base-paired tags and anti-tags, which were selected bioinformatically to 
prevent unspecific hybridization.  The critical step in our approach was adequate binding of the 
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extension primers to diverse field isolates. The efficiency of the extension reaction depends on 
the number and positions of mismatches within an extension primer. An increasing number of 
mismatches will lead to decreasing signal strength or finally to a missing data point. Facing these 
problems  of  homology  were  the  major  challenges  in  developing  this  genotyping  chip.  The 
overall aim of this development was to provide a cheaper alternative to classical sequencing for 
resource poor setting, by typing only the minimal essential SNPs. 
HIV-1 samples from Tanzania were used to design extension primers for 25 SNPs with the aim 
to reduce mismatches between field isolates and primers.  We were able to correctly identify 
92% of all data points. Because hybridization on microarray between perfectly matching and 
optimized  sequences  likely  does  not  cause  any sensitivity  problem,  we assumed  suboptimal 
primer annealing due to mismatches to be responsible for the missing data and we investigated 
the number of mismatches between primers and in the corresponding sequences for some of the 
SNPs that  have failed.  We found that  the occurrence of  more  than 3 mismatches  within an 
extension primer was detrimental to the PCR efficiency, while less than three primer mismatches 
located in the central position of the primer did not greatly affect PCR efficiency. Also primer 
mismatches located as close as 3 nucleotide from the 3` end compromised PCR efficiency. 
When omitting results from extension primers, which never produces signals in the microarray 
(corresponding to 187/2550 SNPs), the concordance of microarray and sequencing increased to 
98%. To overcome excessive mismatches, we designed additional primers specific for individual 
lineages of similar sequences. For SNP K210W, 8 different extension primers were added to the 
multiplexed extension reaction, but we failed to reliably produce typing results for this SNP in a 
hypervariable region. However, for other SNPs our approach of using >1 extension primers and 
to incorporate wobbles at polymorphic positions resulted in an increase in signal production, e.g. 
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designing 5 primers for Y181C  led to 96.1% congruence, and 4 primers for K103N led to 93.1% 
congruence.
The major task in further development of this microarray will be to reduce missing data. This 
may be achieved by designing additional extension primers or by optimizing primer annealing 
conditions,  i.e.  annealing  temperature  and  duration,  or  salt  concentration  in  the  multiplex 
extension reaction. The advantage of a microarray with spotted anti-tags is that it is flexible to 
permit the addition of more tagged extension primers into the reaction, in case one single primer 
cannot  cover  all  sequence  diversity  in  this  particular  region.  Similarly,  additional  extension 
primers for new SNPs can be easily added, provided suitable free anti-tags are available on the 
array. On the other hand, the development of this microarray depended greatly on the availability 
of a large number of nucleotide sequences. Such comprehensive sequencing data to inform about 
polymorphism up and downstream of  a  targeted  SNP is  critical  for  the  design  of  extension 
primers. 
This  SNP-chip  was  developed  primarily  for  population  studies,  e.g.  for  determining  the 
prevalence of transmitted DR-SNPs, or for identifying reasons for treatment failure. For such 
questions, the restricted data obtained by this method is adequate. For other research question or 
for  individual  diagnosis  direct  sequencing  is  more  advantageous,  because  much  additional 
information  is  gained.  The  obvious  advantages  of  genotyping  by  microarray  over  direct 
sequencing are its simplicity, once it is set up; slides are easy to store and consumables (slides 
and reagents) are cheaper than sequencing materials; in particular the equipment required is less 
pricy. Moreover, the microarray typing protocol is faster than sequencing, with about 2 hours per 
12 samples from the completed PCR purification step to obtaining results. 
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1.38 CONCLUSION
Genotyping by microarray has shown good agreement with sequencing in >100 field samples. To 
reliably generate complete DR haplotypes, further optimization is required. Given the simplicity 
of its use, low running costs and short processing time to results, this microarray platform has 
potential  as  alternative  tool  for  monitoring  resistance  mutations  in  population-wide  studies. 
Provided sequence information is available from other regions or other countries, the required 
extension primers can be quickly adapted to local HIV-1 variants.
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Table 4-15: Composition of Extension Primer and ddNTP reaction mixes
Extension Primer Mix 1 Extension Primer Mix 2
T-2-A-M41L ATTTTTGAAATTTTTCCTTCCTTTTCCA T-1-A_K103N CCCACATCCAGTACTGTCACTGATTT 
T-3-S_K65R  TATAACACTCCAGTATTTGCCATAAAAA T-5-A_D67E AAATCTACTAATTTTCTCCACTTAGTACT 
T-4-A_D67N  ATCTACTAATTTTCTCCACTTAGTACTGT T-8-A_L74V  TCTTTTATTGAGTTCTCTGAAATCTACTA
T-6-A_K70R TCCCTGAAATCTACTAATTTTCTCCACT T-10-A_L100I AGTACTGTCACTGATTTTTTCTTTTTTA
T-7-S_K70R ATTTGCCATAAAAAAGAAGGACAGTACTA T-13-S_Y188L2  ATCTATCAATACATGGATGACTTGT 
T-9-A_V75I AGTTCTTTTATTGAGTTCTCTGAAATCTA 
T-15-S_G190A 
TCTATCAATACATGGATGACTTGTATGTA
T-11-S_Y181C 
TAGAGCACAAAATCCAGAAATAGTTATCT T-16-S_L210W AGAGGAGTTAAGAGCACATCTAT 
T-12-A_Y188L1 TGCCCTATTTCTAAGTCAGATCCTAC
T-18-S_T215FY1 
TAAGAGGACATCTATTGAGGTGGGGATTT 
T-14-A-G190A 
CTCTATGCTGCCCTATTTCTAAGTCAGAT T-19-A-K219Q ATGGAGGTTCTTTCTGATGTTTYT
T-17-A_T215FY1  TTCTGATGTTTCTTGTCTGGTGTG T-20-S_M41L AGTGACAGTACTGGATGTGGGGG 
T-23-A_T215FY2 
TTCTTTCTGATGTTTCTTGTCTGGTGTG
T-21-S_T215FY 
AGAGGACATCTATTGAGGTGGGGATTTA
T-24-A_L74I CTTTTATTGAGTTCTCTGAAATCTACTA T-22-A_T215FY TTCTGATGTTTTTTGTCTGGTGTG 
T-28-S_184I AACCCAGAAATAGTTATCTATCAATATAT T-27-A_K219N GAAATGGAGGTTCTTTCTGATGTTT
T-29-A_184V 
TAAATCAGATCCTACATACAAGTCATCCA T-31-S_L74V AAGGACAGTACTAAGTGGAGAAAA 
T-30-S_L74I AAGAAGGACAGTACTAAGTGGAGAAAA T-33-S_L100I GGATACCACACCCAGCAGGG  
T-32-S_L75I AAGGACAGTACTAAGTGGAGAAAATTA T-33.2-S-L100I GGATACCACACCCAGCGGGG
160L74I1.1 ATTGAGTTCCCTGAAATCTACTA T-34-S-K103N  ACACCCAGCAGGGTTGAAAAAGAA 
78M184V1.1 AGATCCTACATACAAATCATCCA
17M41L1.1 
TTTGTAATTTTTCCTTCCTTTTCCA 
144K219E1.1 TGGGGATTTACCACACCAGAC 02K103N1.1 ACATCCAGTACTGTCACTGATTT 
T-02.1-A-Y181C ACATACAAGTCATCCATATATTGA 130L210W1.1 TCTGGTGTGGTAAATCCCCATTTI 
T-38-A-Y181C ACATACAAGTCATCCATGTATTGA T-39-S-L210W  AGAGGAGTTAAGAGCACAYTTAT
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T-40-A-Y181C ACATACAAGTCATCCACATATTGA T-38-S_L210W AGAGGAGTTAAGAGCACATCTsT
T-45.1-A-Y181C ACATACAAGTCATCCACATATTGA
T-41-A-L210W 
TCTCGTCTGGAGTGAAAAATCCCCATTTT
T-45-A-Y181C CATACAAGTCATCCACATATTGG T-42-S-L210W AGAGGAGTTAAGAGCWCACCTAT  
T-50-S-L100I GGATACCACACCCAGCAGGI T-43-S-L210W  AGAGGAGTTAAGAGCWCATCTAT 
T-44-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCATTTC
T-46-S-K219Q TGGGGATTTACCACACCAGAI
T-47-A-L210W 
TTTTGTCTGGTGTGGTAAACCCCCACTTC
T-49-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCACCTT
T-51-S- K219Q TGGGGATTTACCACACCAGAC
Dideoxy-dNTP Mix 1 dideoxy-dNTP Mix 2
ddATP-CY3 ddUTP-CY3
ddCTP-CY3 ddCTP-CY3
ddGTP-CY5 ddATP-CY5
ddUTP-CY5 ddGTP-CY5
Table 4-16: Supplementary Table 1: List of extension primers, tags and anti-tags and 
spotting and hybridization controls.
Extension Primer (5´→3´) Tag (5´→3´) Anti-Tag (5´→3´)
T-1-A_K103N 
CCCACATCCAGTACTGTCACTGATTT T-1 GGTTCCCGATTTATCGATCCC
AT-1 
GGGATCGATAAATCGGGAACC
T-2-A-M41L 
ATTTTTGAAATTTTTCCTTCCTTTTCCA
T-2 
CATGTGGTACAATGGAACAGCTA
CT
AT-2 
AGTAGCTGTTCCATTGTACCA
CATG
T-3-S_K65R 
TATAACACTCCAGTATTTGCCATAAAAA T-3 TCAGGGAACTTCGATGCTGC
AT-3 
GCAGCATCGAAGTTCCCTGA
T-4-A_D67N T-4 GACTGACCCGCTTGAGTTAGT AT-4 
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ATCTACTAATTTTCTCCACTTAGTACTG
T
ACTAACTCAAGCGGGTCAGT
C
T-5-A_D67E 
AAATCTACTAATTTTCTCCACTTAGTAC
T
T-5 
GTTCAATCAGAAAACACCTGCGG
AT-5 
CCGCAGGTGTTTTCTGATTGA
AC
T-6-A_K70R 
TCCCTGAAATCTACTAATTTTCTCCACT T-6 CTGCAAGCAGGTTGTGCTCT
AT-6 
AGAGCACAACCTGCTTGCAG
T-7-S_K70R 
ATTTGCCATAAAAAAGAAGGACAGTAC
TA T-7 GGCGGTTCATGGAATTCCC
AT-7 
GGGAATTCCATGAACCGCC
T-8-A_L74V 
TCTTTTATTGAGTTCTCTGAAATCTACT
A
T-8 
GTCCTACGTCGAGTAGAGAAAGT
C
AT-8 
GACTTTCTCTACTCGACGTAG
GAC
T-9-A_V75I 
AGTTCTTTTATTGAGTTCTCTGAAATCT
A
T-9 
CATTTGCGTTTCTCTGGGTAATGC
AT-9 
GCATTACCCAGAGAAACGCA
AATG
T-10-A_L100I 
AGTACTGTCACTGATTTTTTCTTTTTTR T-10 CCTGTCGGGAGCAGTACA
AT-10 
TGTACTGCTCCCGACAGG
T-11-S_Y181C 
TAGAGCACAAAATCCAGAAATAGTTAT
CT
T-11 
ATCTACTACCACCTCCAACGG
AT-11 
CCGTTGGAGGTGGTAGTAGA
T
T-12-A_Y188L1 
TGCCCTATTTCTAAGTCAGATCCTAC
T-12 
GGGCGGACTACATCGAAATTACC
AT-12 
GGTAATTTCGATGTAGTCCG
CCC
T-13-S_Y188L2 
ATCTATCAATACATGGATGACTTGT 
T-13 
CCGAAACAACGCAGAACTCAC
AT-13 
GTGAGTTCTGCGTTGTTTCG
G
T-14-A-G190A 
CTCTATGCTGCCCTATTTCTAAGTCAG
AT T-14 CTCTCCACAGTGCAGCGA
AT-14 
TCGCTGCACTGTGGAGAG
T-15-S_G190A 
TCTATCAATACATGGATGACTTGTATGT
A T-15 TGGCCTTGTGAATCCACCC
AT-15 
GGGTGGATTCACAAGGCCA
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T-16-S_L210W 
AGAGGAGTTAAGAGCACATCTAT1
T-16 
CGAAAAACCACGCCGTATTTCA
AT-16 
TGAAATACGGCGTGGTTTTTC
G
T-17-A_T215FY1 
TTCTGATGTTTCTTGTCTGGTGTG
T-17 
TCACTTACGACCGTTTTGTCTACA
AT-17 
TGTAGACAAAACGGTCGTAA
GTGA
T-18-S_T215FY1 
TAAGAGGACATCTATTGAGGTGGGGAY
TT T-18 GAGAGGCATGCGTTTCACG
AT-18 
CGTGAAACGCATGCCTCTC
T-19-A-K219Q 
ATGGAGGTTCTTTCTGATGTTTYT
T-19 
GACCGGCAATTCGTTATCCAC
AT-19 
GTGGATAACGAATTGCCGGT
C
T-20-S_M41L 
AGTGACAGTACTGGATGTGGGGG
T-20 
GTCAAATTCGACAGCTGGAAGG
AT-20 
CCTTCCAGCTGTCGAATTTGA
C
T-21-S_T215FY 
AGAGGACATCTATTGAGGTGGGGATTT
A
T-21 
GAAGCCGTCTCTGTTGTTTTCC
AT-21 
GGAAAACAACAGAGACGGCT
TC
T-22-A_T215FY 
TTCTGATGTTTTTTGTCTGGTGTI T-22 CAGAGATCCATTGGCGCGT
AT-22 
ACGCGCCAATGGATCTCTG
T-23-A_T215FY2 
TTCTTTCTGATGTTTCTTGTCTGGTGTY
T-23 
CGCATAATGACCCAACTTCGAG
AT-23 
CTCGAAGTTGGGTCATTATG
CG
T-24-A_L74I 
CTTTTATTGAGTTCTCTGAAATCTACTA T-24 GCTGCCGGCTATTTTTGGAG
AT-24 
CTCCAAAAATAGCCGGCAGC
T-27-A_K219N 
GAAATGGAGGTTCTTTCTGATGTTT
T-27 
CCCCCGAGAAGGTTTATGTTTAAC
AT-27 
GTTAAACATAAACCTTCTCGG
GGG
T-28-S_184I 
AACCCAGAAATAGTTATCTATCAATATA
T T-28 AGCCTCGGGTCTACATCGT
AT-28 
ACGATGTAGACCCGAGGCT
T-29-A_184V 
TAAATCAGATCCTACATACAAGTCATC
T-29 CAGCAGTCCGATGCCTGG AT-29 
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CA CCAGGCATCGGACTGCTG
T-30-S_L74I 
AAGAAGGACAGTACTAAGTGGAGAAAA
T-30 
CGCCTAGACCTTTTAGCTAGCC
AT-30 
GGCTAGCTAAAAGGTCTAGG
CG
T-31-S_L74V 
AAGGACAGTACTAAGTGGAGAAAA T-31 GGAGCTTTTGCTGTTCGGTC
AT-31 
GACCGAACAGCAAAAGCTCC
T-32-S_L75I 
AAGGACAGTACTAAGTGGAGAAAATTA
T-32 
CGGGGTATGACATACTATTGACCA
AT-32 
TGGTCAATAGTATGTCATACC
CCG
T-33-S_L100I 
GGATACCACACCCAGCAGGG T-33 GTTGGCGGGTTATTACAGGG
AT-33 
CCCTGTAATAACCCGCCAAC
T-34-S-K103N 
ACACCCAGCAGGGTTGAAAAAGAA T-34 TGCGATTGTATACCCGCTCC
AT-34 
GGAGCGGGTATACAATCGCA
AT-35 
GCGTAAATCATACGCCTGGG
TC2
AT-36 
ACGCGTTACGTTAGAGATAA
GGCTA2
AT-37 
GCCTCCACCCTTCTCAAGAAT
A2
T-38-S_L210W 
AGAGGAGTTAAGAGCACATCTsT1
T-38 TTTCCGGATTCACCCGTACC
AT-38 
GGTACGGGTGAATCCGGAAA
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T-39-S-Y181C 
TAGAGCACAAAATCCAGAAATAGTTAT
wT T-39 GATCGGACGACGCTTGGG
AT-39 
CCCAAGCGTCGTCCGATC
T-40-A-Y181C 
ACATACAAGTCATCCACATATTGA T-40 TAGAGGAGGCGGGAGTTTTT
AT-40 
AAAAACTCCCGCCTCCTCTA
T-41-A-L210W 
TCTCGTCTGGAGTGAAAAATCCCCATT
TT1
T-41 
AGCCAATGAATGACAATTCGTGCA
AT-41 
TGCACGAATTGTCATTCATTG
GCT
T-42 GCACCACAGTCCGGTATTGC
AT-42 
GCAATACCGGACTGTGGTGC
T-43-A-K103N  CC CAC ATC CAA TAC 
TGT TAC TGA CTT T-43 TTTCACACACGGCCACTTTTC
AT-43 
GAAAAGTGGCCGTGTGTGAA
A
T-44-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCATT
TC1
T-44 
TGTTTGAACTAGTGGCGTCACG
AT-44 
CGTGACGCCACTAGTTCAAA
CA
T-45-A-Y181C 
CATACAAGTCATCCACATATTGG T-45 GGTGATAGGCAACGAGGTCT
AT-45 
AGACCTCGTTGCCTATCACC
T-46-S-K219Q 
TGGGGATTTACCACACCAGAI
T-46 
GGGGATCCTAGACTTTGATGCT
AT-46 
AGCATCAAAGTCTAGGATCC
CC
T-47-A-L210W 
TTTTGTCTGGTGTGGTAAACCCCCACT
TC1
T-47 
CTTAGTCCTCTGACTGTCTCTGTC
AT-47 
GACAGAGACAGTCAGAGGAC
TAAG
AT-48 
GACACACTTGTTGGACGCAA
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G2
T-49-A-L210W 
TCTTGTCTGGTGTGGTAAATCCCCACC
TT1
T-49 
GTGTTTGTCTACTTCGTGTGTGC
AT-49 
GCACACACGAAGTAGACAAA
CAC
T-50-S-L100I 
GGATACCACACCCAGCAGGI
T-50 
ATGGAACCTATAATCTAGGATGGC
G
AT-50 
CGCCATCCTAGATTATAGGTT
CCAT
T-51-A-L210W 
TTTTGTCTGGGGTAGTCAATCCCCAGC
TC1
T-51 
TCGTATAAGTCACGTTCTCCTTGG
AT-51 
CCAAGGAGAACGTGACTTAT
ACGA
AT-52 
CATTACTCCCTCCCGTCATGT
2
17M41L1.1 
TTTGTAATTTTTCCTTCCTTTTCCA
17.1 
CAACATCATCACGCAGAGCATCAT
T
17.1 
AATGATGCTCTGCGTGATGAT
GTTG
160L74I1.1 
ATTGAGTTCCCTGAAATCTACTA
160.1 
CCACGTACTGTCCGGAATACACG
AC
160.1 
GTCGTGTATTCCGGACAGTA
CGTGG
02K103N1.1 
ACATCCAGTACTGTCACTGATTT
02.1 
TGCCCCGTTGCCCCGTTGCCCCG
T
02.1 
ACGGGGCAACGGGGCAACG
GGGCA
75Y181C1.1 
CATACAAGTCATCCATATATTGA
75.1 
TAACACAAGAGCAGCTTGAGGAC
G
75.1 
CGTCCTCAAGCTGCTCTTGT
GTTA
78M184V1.1 
AGATCCTACATACAAATCATCCA
78.1 
ACAGCCTCGCAGATGACGAATCA
TT
78.1 
AATGATTCGTCATCTGCGAG
GCTGT
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130L210W1.1 
TCTGGTGTGGTAAATCCCCATTTI1
130.1.1 
TACCAACTGTATGCGCATGTGCAC
C
130.1.1 
GGTGCACATGCGCATACAGT
TGGTA
144K219E1.1 
TGGGGATTTACCACACCAGAC
144.1.1 
TTCAGTGTATGACGACCAGAGCG
TT
144.1.1 
AACGCTCTGGTCGTCATACA
CTGAA
[Cy3]AGAAGATGCCTAGTATATG
AT-61 
CATATACTAGGCATCTTCT
[Cy5]ATGCAACCATCAAGT-
[AmC7~Q]
[Cy3] 
GCTCAGCTGTATTAGAA- 
[AmC7~Q]
1 Extension primers never giving a signal or with inconsistent performance
2 5 additional anti-tags were designed and spotted to permit future use; these were utilized for 
quantification of background hybridization)
Table 4-17: Supplimentary Table 2: Comparison of microarray with direct sequencing 
using field samples and cloned DNA fragments.
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Field Samples
ET33 1 0 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22
ET34 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 23
ET36 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 24
ET37 1 0 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22
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ET39 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 22
ET44 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
ET48 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 22
ET50 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
ET53 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23
ET56 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
ET59 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 23
5510266 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
5510423 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 22
5510599 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 21
5510305 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22
5510377 1 0 1 1 1 1 1 0 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 20
5510376 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
5510388 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23
5511611 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
5410055 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
5510060 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23
5510184 1 0 1 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 0 1 1 1 21
5510603 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23
FTM 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22
5510508 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 22
5510026 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
5510817 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
5510236 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
5510718 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 22
5510504 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 22
5510075 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
5510270 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 21
5510135 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 23
5514370 1 1 1 1 1 1 1 1 1 0 0 0 1 0 0 1 1 1 1 0 1 1 0 1 1 18
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HLM5 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23
HLM 6 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 21
HLM 7 1 1 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 0 0 1 1 1 21
HLM 13 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 23
HLM 17 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 1 1 23
HLM 23 1 0 1 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 21
HLM 25 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM 27 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM29 1 0 1 1 1 1 1 1 1 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22
ET 2 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 1 1 1 20
HLM 32 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 35 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM 36 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 38 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 41 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 69 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 71 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
HLM 73 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 74 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM76 1 1 0 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23
HLM 77 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
HLM 78 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
HLM 79 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 80 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 83 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23
HLM 86 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM 87 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
HLM 88 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
 ET 7 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 0 1 1 19
 ET 7 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 1 0 1 1 1 1 1 0 1 1 19
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5514352 1 0 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 0 0 1 1 1 1 20
5510255 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 0 1 1 1 22
5511110 1 1 0 1 1 1 1 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 0 1 1 18
5514391 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23
HLM-89 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-91 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-92 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-93 1 0 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 23
HLM-172 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-173 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-175 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-176 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 24
HLM-177 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-178 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-180 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 23
HLM-181 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-182 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-185 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-258 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
HLM-259 1 1 1 1 1 1 1 1 1 1 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 22
HLM-260 1 1 1 1 1 1 1 1 1 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 22
HLM-261 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 0 1 1 22
HLM-262 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 23
HLM-263 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-264 1 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 23
HLM-265 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 24
HLM-267 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-182 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-271 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23
HLM-267 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
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HLM-182 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
HLM-271 1 0 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 23
05510783-A 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 24
5510075 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 23
 ET 7 1 0 1 1 1 1 1 1 1 0 0 1 1 0 1 1 1 1 1 0 1 1 0 1 1 19
HLM 88 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 24
HLM 80 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
07510783-B 1 1 1 1 0 1 1 1 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 22
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Cloned RT Fragments
0720235-C1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
6017225-AE2 1 1 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 0 1 0 1 1 1 1 22
072073-C1 1 0 1 1 1 1 1 0 0 0 1 0 1 0 1 1 1 1 1 0 1 1 1 1 1 18
070510-A2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25
agreement 4 3 4 4 4 4 4 3 3 3 3 3 4 3 4 4 4 4 3 3 3 4 4 4 4 90
Fig. 2 Fig. 3 119
Development for a Microarray for Genotyping HIV-1 Drug Resistance Mutations in the Reverse 
Transcriptase Gene
A B
Figure 4-12: HIV-1 SNP typing microarray  (Figure A and B)  
 HIV-1 SNP typing microarray. (A) Design and layout of microarray. Triplicates are depicted in 
different colours. T1, TC59, TC60, T61 and blnk denote Cy5 spotting control-2, Cy5 spotting 
control-1, Cy3 spotting control, Cy3 pre-labeled hybridization control and printed buffer spots 
(blank), respectively.  Some of the anti-tags were not in use in this experiment (T35, T36, T37, 
T48 and T52) and therefore utilized as negative control for calculating the cut-off. (B) Image of a 
HIV-1 SNP typing microarray after hybridization with a Tanzanian field sample.  Each array 
consists  of  14x14  spots.  Cy5  spotting  control  (degenerated,  indicated  by  red  circles);  Cy3 
spotting control (green circles); Cy5-prelabeled hybridization control (blue circle); example of 
missing data (white circle)).  
120
Development for a Microarray for Genotyping HIV-1 Drug Resistance Mutations in the Reverse 
Transcriptase Gene
∼1000bp
 
 ∼500bp
    
Ladder DNA
                 217bp
                           56bp
                                   134bp
                                           136bp
                                                 144bp
                                                          155bp
                                                                  158bp
                                                                           233bp
                                                                                    499bp
                                                                                          504bp
                                                                                                   579bp
                                                                                                          66bp
                                                                                                                579bp
                                                                                                                      645bp
                                                                                                               Ladder DNA
Figure 4-13: Supplementary Figure 1: Validation of extension primers by PCR on cloned 
RT fragments and viral cDNA from Tanzania. Expected fragment sizes range from 56- 645 
bp.
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1.41 DISCUSSION
The  WHO recommends  monitoring  of  HIV-1  drug  resistance  for  the  effectiveness  of  ART 
programmes.  Monitoring  of  HIV-1  drug  resistance  allows  optimization  of  the  available 
therapeutic  options  and  provides  epidemiological  data  to  describe  the  magnitude  of  HIV-1 
resistance in the population. These epidemiological data can also be used to develop appropriate 
strategies that can limit the spread of the resistant strains. In view of the above it was intended in 
this  study  to  monitor  drug  resistance  in  an  established  HIV-1  cohort  in  a  rural  setting  of 
Tanzania. 
In the course of this PhD project three studies were conducted: (i) sequencing  the RT and PR 
genes from a total of 387 samples from drug naïve patients so as to establish the prevalence of 
HIV-1 DR-SNPS (primary or transmitted drug resistance) and HIV-1 subtypes in these two time 
period  (2005-7  and  2009)  (ii)   genotyping  follow  up  samples  from   patients  under  ART, 
including presumptive cases of drug resistance,  to establish the prevalence of DR-SNPs after 
initiation of ART (aquired resistance), and (iii) using an alternative, microarray-based approach 
to genotype samples from drug naïve patients. 
The first paper as indicated in chapter 2 of the thesis, describes the prevalence of HIV-1 subtypes 
and drug resistance mutation in drug naïve patients. In 2005-2007 a total of 187 patient samples 
were used, out of which 119 (63.6%) could yield final sequences for subsequent analysis. In 
2009, 200 patient samples were used and 120 samples (60%) were successfully sequenced for 
data analysis. A high level of PCR negativity was encountered in drug naïve patients and was 
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equally high at both time points. This could be caused by problems in storage of these samples in 
Ifakara. In KIULARCO activities, frequent interruptions of power supply were reported from the 
IHI laboratory (Edit Horvath personal communication). This could have led to degradation of 
RNA in some of the samples. In addition, plasma separations from the patient blood samples 
were  suboptimal,  because  quite  a  number  of  plasma samples  were  red in  colour  suggesting 
haemolysis. This indicates that blood samples might have been left on the bench for too long 
time, despite the recommendation that the processing time should not greatly exceed 1-2 hours. 
It is likely that such suboptimal sample processing together with repeated cycles of freeze and 
thaw due to power cuts, had a negative impact on the outcomes of our PCR experiments. 
Our analysis  of subtypes in KIULRCO showed agreement with other reports from Tanzania.  
Prevalence of HIV-1 subtypes did not vary significantly between the two periods compared, with 
the exception of the occurrence of HIV-1 subtpe B and F in 2010. Our results are in agreement  
with  other  studies  in  Tanzania  which  have  shown that  subtypes  C,  A  and  D are  the  most 
prevalent subtypes in Tanzania [108] [109]. The minor differences between our HIV subtype 
distribution  and  that  from  other  studies  conducted  in  Tanzania  could  be  explained  by  the 
sequenced fragment of the viral genome used by us for subtype determination. We have based 
our  subtype  analysis  on  the  pol region  only.  This  approach  is  prone  to  underestimate 
recombinant forms [110] [112]. But the pol region  has been used for this purpose also by other 
researchers, because  it has the advantage of providing information on drug resistance mutations 
as well as subtype information, both based on the same sequence [112] [113]. 
DR mutations were observed at both time intervals analysed.   The prevalence of major NRT 
mutations  was 5.9% in 2005-2007 and 1.7% in 2009. This difference in prevalence was not 
statistically significant (p=0.102). Similarly, prevalence of NNRT mutations was 9.2% in 2005-
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2007 and 3.3% in 2009, again this difference did not reach statistical significance (p = 0.0671). 
A  higher  number  of  patients  in  the  clinically  more  severe  WHO  stages  3  and  4  could  be 
responsible  for  the  higher  number  of  DR-SNPs.  This  suggests  that  right  at  the  start  of 
KIULARCO activities a specific group of HIV patients might have entered the CDCI. This is 
supported  by observed differences  in  mean  CD4 counts  between the two groups of  patients 
compared. In contrast, the finding of similar viral load between both sets of patients disagrees 
with the assumption of two distinct groups of patients. An explanation for low viral loads at the 
earlier time point despite lower CD4 counts could be the earlier mentioned problems in long 
term storage of plasma. 
All individuals with DR-SNPs in 2009 and 60% of individuals in 2005-2007 carried the K103N 
mutation. We do not know the reasons for the high prevalence of this K103N mutation but this 
could be due to prior use of nevirapine monotherapy for PMTCT in Tanzania [92] and in the area 
(Marcel Stoeckle personal communication). It has been observed in other studies that the use of 
nevirapine monotherapy for PMCTC could lead to the selection of this K103N mutation [96]. 
The  observed  level  of  primary  resistance  must  be  considered  as  a  potential  threat  to  the 
efficiency of the KIULARCO and Tanzania ART programmes. 
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The second paper (Thesis chapter 3) describes prevalence of DR-SNPs in 137 follow up samples 
from 2005-2007 patients. The average time of ART intake at the time of collecting the follow up 
sample was 11.6 months. These follow up patients had been on first line regimen containing 
starvudine + lamivudine + nevirapine (87.4%), zidovudine + lamivudine + nevirapine (6.3%) or 
emtricitabine + tenofovir disoproxil fumarate + effavirenz (6.3%). The rationale for this study 
was to investigate a potential development of acquired resistance following ART usage in the 
area. Such information could contribute to an assessment of the effectiveness of drug regimens 
supplied  in KIULARCO.  
The PR and RT genes were successfully PCR amplified and sequenced in 16 out of 137 (11.7%) 
patient samples. In those 16 sequenced samples, 2 (12.5%) sequences harboured major DR-SNPs 
to RTIs, while six other sequences harboured minor DR-SNPs to RTIs. All the six (2 patients 
with major and 6 with minor mutations) patients with RT mutations had been on ART regimen 
containing nevirapine-based combination for a mean period of 19 months. Studies conducted in 
other  parts  of  Tanzania  and  East  Africa  had  revealed  variable  levels  of  resistance  in  ART 
experienced  patients.  For  example,  one  study  conducted  in  Haydom  Lutheran  hospital,  in 
Manyara, North-East rural Tanzania [96] detected HIV-1 resistance mutations at a rate of 3.9% 
after  1  year  of  ART usage.  This  low level  of  resistance  in  Hydom  was  due  to  adherence 
counseling,  presence  of  home-based  carers,  regular  peer-support  meetings,  and  continuous 
uninterrupted  drug  supply.  In  another  study  conducted  in  Kampala  urban  in  Uganda  [115] 
revealed a prevalence of 72% of PCR and sequencing positive patients  on ART for average 
period of 37.7 weeks. This variability can be explained by the fact that in Uganda study 23.4% of 
participants had interrupted their doses for duration of more than four days and this was shown to 
be  strongly  associated  with  treatment  failure.  Our  resistance  findings  were  higher  than  that 
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obtained in Hydom but lower than that observed in Uganda study, suggesting that the data we 
obtained was in the range of values obtained from these two studies.
Following observation of clinical resistance in KIULARCO patients, samples collected at the 
time of suspected DR were genotyped for DR-SNPs.  Six out of 17 patient samples harboured 
major DR-SNPs to RTIs and at least one minor RTI mutation. In addition, viral sequences from 2 
patient samples (11.8%) carried minor DR-SNPs to PRIs. The majority of the 17 patients (11 
patients)  did not harbour any DR-SNPs suggesting that the clinical failure observed in these 
patients was not due to acquisition of viral drug resistance. Several factors such as drug toxicity,  
use of low potent drugs, non-adherence and long duration of ART are known to risk factors 
contributing to development of resistance in HIV-1 treated patients [116]. Of these factors, only 
adherence  was  recorded  in  the  subset  of  KIULARCO  patients  studied  and  in  general  the 
adherence reported was good. Adherence information was extracted from medical reports, but 
this cannot rule out the possibility of missed doses. Other factors associated with resistance were 
not evaluated in this study. 
Thesis  chapter  four  presents  a  microarray-based  genotyping  approach  as  an  alternative  to 
sequencing.  A  hallmark  of  this  approach  was  to  adapt  all  hybridization  probes  to  locally 
prevalent HIV variants. Sequence alignments of the 126 viral isolates from drug naïve patients 
were used to design extension primers for microarray optimization. Using sequence information 
from  KIULARCO  samples  was  a  prerequisite  in  the  optimization  process,  since  marked 
sequence  variation  could  affect  the  performance  of  the  primer  extension  reaction.  By 
minisequencing at the 3’ end of the designed oligonucleotides mutations in the RT gene were 
detected. The direction of these extension primers was either directly the 5' or directly the 3' of  
the  targeted  SNP.  The  choice  of  either  of  the  two  possible  primers  was  based  on  optimal 
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sequence conservation in the alignment of the 126 sequences. The length of extension primers 
varied to minimize variation in melting temperatures of all extension primers. This was required 
because all extension primers were used in a multiplex extension reaction. A total of 25 SNPs in 
the RT gene representing the most  important  mutations  for drugs used in KIULARCO were 
targeted. To maximize sensitivity, up to six different extension primers were designed to target a 
single  SNP.  This  number  depended  on  the  number  of  mismatches  observed  in  sequence 
alignment.  The aim was to  provide  per  SNP confirmatory  results  from 2  extension  primers 
placed in opposite directions of the targeted position 
The microarray was validated by using 4 cloned fragments which had been generated previously 
in  the course of  a  phenotyping assay established for  samples  from the Swiss HIV-1 cohort. 
Because cloned inserts represent a single template, this material was considered highly suitable 
to validate the specificity of hybridization on microarray and to determine individual anti-tags 
that  give  rise  to  hybridization  background.  When  using  the  cloned  material  the  agreement 
between  the  microarray  and direct  sequencing  was  90%.  The result  varied  for  the  different 
cloned fragments. With 2 plasmids containing a RT fragment of C1 and A2 subtype (0720235-
C1 and 070510-A2) perfect agreement between sequence and microarray genotype was obtained, 
whereas only 88% concordance was reached for a plasmid with a AE2 subtype insert (6017225-
AE2) and 72% for a subtype C1 insert (072073-C1). Because these plasmid inserts derived from 
patients  in  a  Swiss  HIV  cohort,  they  likely  represented  variants  with  substantial  genetical 
distance to the extension primer sequence that had been optimized for Tanzanian subtypes.
The  performance  of  the  HIV microarray  was  principally  validated  by  genotyping  102  field 
samples from HIV-1 patients from a HIV cohort in Ifakara, Tanzania. The agreement between 
microarray  and  direct  sequencing  was  92.7%.  Five  extension  primers  (i.e.  SNPs)  had 
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concordance of 100%, fourteen SNPs had concordance of more than 90% and only one SNP had 
concordance of less than 70%.  Extension primers that were designed for K210W, Y188L, K65R 
and K219N performed sub-optimally in  this  microarray with an efficiency of 62.7% 71.6%, 
75.5%, and 78.4%, respectively. 
Several difficulties were encountered in the micorarray development and optimization process. 
One of  the  challenges  was missing  data,  likely  due to  an exceeding  number  of  mismatches 
between isolate and sequence in case of an extension primer positioned at a region of imperfect 
sequence conservation. This problem is entirely due to the well-known extreme diversity among 
HIV genomes. This seems to apply even for HIV variants from a restricted population. Similarly, 
it  was  challenging  to  generate  uniform  signal  intensities  for  all  spots  of  the  microarray. 
Differences in slide pretreatment conditions and duration of slide storage could have contributed 
to these difficulties.
In summary, the viral sequence diversity will inevitably lead to missing data in SNP calling due 
to inefficient hybridization during the primer extension step. Depending on the sequence of a 
particular isolate, it is likely that one or more data points might be missing. HIV genotyping on 
our microarray in its current form must be considered, due to biological reasons of sequence 
variation,  an imperfect  tool.  Yet,  the agreement  of >90% with sequencing results  suggests a 
possible role of this tool in molecular epidemiological studies, where missing data, if it is not 
systematic, causes less problems. The further use of this tool greatly depends on the genotyping 
techniques  available  and  on  costs  of  the  microarray  technique  versus  costs  of  sequencing. 
Because the latter  costs have decreased substantially over the past years,  it  seems likely that 
sequencing and next generation sequencing will be widely available and affordable in future. 
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1.42 CONCLUSION  
The molecular work in this study has provided the first baseline information on HIV-1 strains 
encountered  in Ifakara,  a rural  area in  Southern Tanzania.  The study has shown a relatively 
stable subtype distribution (C, A, D and CRF01_AE) within 5 year period in the area. In 2009, 
however, there was introduction of new subtypes B and F at frequencies lower < 5% and these 
subtypes  are very rare in Tanzania.  The generated subtype distribution information adds and 
contributes to the already existing data of HIV-1 distribution in Tanzania, especially so, in rural 
parts of Tanzania.
There was a low prevalence of primary drug resistance mutations and these mutations create a 
low potential threat for the ART programme in the area. The demonstration of the extent and 
significance of HIV-1 drug resistance mutations in treatment naive individuals is useful for an 
informed choice of ART and thus can contribute to efforts towards preventing the spread of drug 
resistance. 
The detection of very low frequencies of DR-SNPs in randomly selected patients who had been 
on ART suggests that the drug combinations deployed by KIULARCO are effective and that no 
major  adherence  problems  prevail.  In  addition,  one-third  of  patients  with  suspected  drug 
resistance harboured DR-SNPs. Since majority of suspected resistance cases were not due to the 
known DR-SNPs, further studies are suggested to investigate and address factors that might have 
contributed to the treatment failures in these patients
The microarray that was developed showed a good sensitivity. Due to the technical simplicity in 
the development,  low running cost,  the easiness of running the experiment,  the shorter time 
required to get results and the flexibility to allow incorporation of new mutations, this microarray 
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platform has a potential to be used as an alternative genotyping tool for monitoring resistance 
mutations  at  a  population  level  in  Ifakara  cohort,  Tanzania  and  also  in  other  developing 
countries.  However  the  main  challenge  encountered  was  missing  data  and  problems  with 
background signals. 
The focus of this work was on primary and acquired resistance that was done in a cross sectional 
study. Next studies should also include longitudinal studies that can provide the dynamics of 
resistance mutations as well as subtype distribution in the area.
Our results highlight the need to conduct studies in KIULARCO on patient adherence to ART so 
as to investigate the possible cause of treatment failure observed in some of our patients. 
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